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1 Introduction 
1.1 Protein quality control 
Cell function and viability are depending on correct protein folding. Although all information 
necessary for a protein to obtain a native conformation is encoded in its amino acid sequence 
(Anfinsen 1973), in vivo protein folding requires the assistance of chaperones, folding catalysts and 
proteases to monitor and regulate this process. Accordingly, cells have developed a sophisticated 
system of chaperones and proteases to control the folding state of proteins (Wickner et al. 1999). 
Failure in the quality control machinery can lead to damaged proteins that can be hazardous for cells 
as they tend to form large aggregates.  
Mistakes in transcription and translation that result in mutations of only one amino acid can lead to 
destabilization and thus prevent normal folding. In addition, environmental stress conditions such as 
macromolecular crowding, inappropriate ionic strength, oxidative, temperature or pH stress can 
cause the formation of misfolded proteins or slowly reacting intermediates (Wickner et al. 1999). 
Stress conditions can also promote the partial unfolding of fully folded native proteins. Exposed 
hydrophobic regions on non-native proteins bind to similar regions on nearby proteins by highly 
specific self association (Rajan et al. 2001). The aggregating species can continue to bind exposed 
hydrophobic regions of neighbouring proteins and form various stable structures, including soluble 
aggregates and insoluble deposits (Demuro et al. 2005). Insoluble protein aggregates contribute to 
the pathology of a variety of serious human diseases, including amyloidoses that are characterized by 
insoluble, fibrillar protein aggregates with a ß-sheet-rich structure. In this situation both proteases 
and chaperones serve to maintain quality control of cellular proteins. Any of the two protein families 
has to recognize regions that are commonly found in misfolded or unfolded proteins but not in native 
proteins (Wickner et al. 1999) and it could be demonstrated, that both systems recognize 
hydrophobic regions exposed in unfolded proteins (Wickner et al. 1999). The number of diseases 
linked to aberrant protein conformations include Huntington’s disease, Alzheimer’s disease, 
Parkinson’s disease, and more (Dobson 2004; Macario and Conway de Macario 2005). They underline 
the importance of an effective protein quality control for cell viability and survival. 
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Fig. 1.1 Principles of protein quality control 
Non-native proteins can either be refolded by molecular chaperones or degraded by proteases. Both principles serve the same goal, 
namely the avoidance of protein aggregates, which are lethal for the cell. Achieving the correct balance between folding and degradation 
of misfolded proteins is critical for cell viability. 
1.2 Proteolysis and proteolytic enzymes 
Proteases are an important class of enzymes that hydrolyse peptide bonds. They can either work as 
exo- or endopeptidases. Exopeptidases cleave one, two or three residues from the N- or C-terminus 
of a polypeptide chain. Therefore they are called aminopeptidases or carboxypeptidases, 
respectively. Endopeptidases cleave somewhere in the middle of a polypeptide chain, depending on 
their substrate specificity. According to the nomenclature of Rawlings and Barrett, endoproteases 
can be divided into five groups depending on their active site residues and their functional groups. 
Four of these groups, namely serine proteases, cysteine proteases, aspartate proteases and 
metalloproteases (Barrett, 1994) have been well studied and are well understood (Rawlings et al. 
1994, 1995, 1995). Proteases perform a variety of fundamental biological activities. They are used for 
such different functions as food digestion, cleavage of signal peptides, the precise processing of 
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proteins in the blood clotting cascade (Fersht 1999) or the degradation of abnormal proteins 
(Wickner et al. 1999). Proteases are furthermore associated with a variety of diseases and therefore 
they are potential targets for new drugs (Fersht 1999).  
The biological implications of proteolytic reactions are immense. Proteases provide an important link 
between genetics and biochemistry as they often act as key players in regulatory events, for example 
in important signaling cascades such as apoptosis (Shi 2002, Degterev et al. 2003) and the regulation 
of the unfolded protein response (Patil et al. 2001). 
Proteases also show a high degree of specificity towards binding and processing their substrates. 
Thereby substrate specificity is often defined by the structural properties of the active site or by 
adaptor proteins that can feed substrates to the protease (Gottesman 2003). Bacterial DegS is an 
example where binding of C-termini of outer membrane proteins to the PDZ domain triggers the 
activation of the protease (Walsh et al. 2003). As mentioned before, proteases bind to hydrophobic 
patches which are normally buried in the native conformation (Wickner et al. 1999). Therefore it is 
obvious that potential cleavage sites have to become accessible as a result of unfolding or the loss of 
interaction partners. A further concept to control the accessibility of catalytic sites is the 
compartmentalization of active sites within a large protease particle. In cage forming proteases, as 
examplified by the proteasome or the DegP protease from E. coli, the active sites are located in an 
inner cavity that can be accessed only by unfolded proteins (Larsen et al. 1997, Clausen et al. 2002, 
Krojer et al. 2008). This principle is an elegant way to prevent degradation of folded proteins. 
Proteases are often involved in degradation events which are depending on the action of more than 
one protease which represents an additional level of regulation. Inhibition and activation of 
proteases describes another principle of regulation. Many of the classical proteases such as trypsin 
are synthesized as inactive zymogens that are converted into the active form by proteolysis of a 
propeptide (Khan et al. 1998, Lazure 2002, Wiederanders 2003). Zymogen activation was long 
considered to be irreversible however, recent reports indicate reversible zymogen activation where 
either other proteins (Friedrich et al. 2003) or external factors such as concentrated salts (Huang et 
al. 2001), temperature (Spiess et al. 1999) and binding of substrates (Ehrmann et al. 2004, 
Hasselblatt et al. 2007, Krojer et al. 2008) can switch protease activity on or off. Yet another level of 
regulation of proteases is the existence of various natural inhibitors. According to the principle of 
exosite binding (Krishnaswamy 2005, Guillin et al. 1995), the common feature of these inhibitors is 
that they are tightly bound to the protease by occupying the substrate-specificity pockets (Bode et al. 
2000, Ye et al. 2001). 
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1.3 Serine proteases 
Serine proteases have been extensively studied and are a group of well-characterized enzymes. They 
have been studied by both by kinetic methods in solution and by x-ray structural studies to high 
resolution. Most of them contain the typical catalytic triad composed of histidine, aspartate and 
serine. So far, also serine proteases with novel catalytic triads, (e.g. Ser-His-His) and dyads (e.g. Ser-
Lys) have been additionally discovered (Blow 1997, Hedstrom 2002, Pólgar 2005). The following 
paragraph gives a short description of the catalytic mechanism and the main determinants of 
substrate specificity of serine proteases considering chymotrypsin as example. It should be noted, 
that this overview is mainly adopted from the book Carl Brandon and John Tooze (Introduction to 
protein structure, 1999) and from Alan Fersht (Structure and mechanism in protein science, 1999) 
and Arthur Lesk (Introduction to protein structure, 2001).  
1.3.1 The catalytic mechanism  
The mechanism for the hydrolysis of the peptide bond is an addition-elimination reaction involving 
two tetrahedral intermediates. The catalytic triad spans the active site cleft with Ser195 on one side 
and Asp102 and His57 on the other side (using the chymotrypsin numbering). The reaction proceeds 
in two steps: during the first step the peptide bond is cleaved. The sidechain of the substrate at the 
residue N-terminal to the scissile bond binds to the specificity pocket and the catalytic triad Asp102-
His57-Ser210 positions and polarizes the sidechain of Ser195 for nucleophilic attack on the C-atom of 
the peptide bond. The C1 of the substrate is covalently bound to the hydroxyl group of the active site 
serine in the protease forming an acyl-enzyme intermediate. The intermediate with the carbon atom 
in a tetrahedral state is stabilized by the ‘oxyanion hole’. Both Gly193 and Ser195 can donate 
backbone hydrogens for hydrogen bonding to the negatively charged oxygen of the substrate 
(formerly the carbonyl oxygen of the peptide group of the peptide bond) (Fig. 1.3). A proton is 
transferred from Ser195 to His57 releasing the C-terminal moiety of the substrate. One peptide 
product is now attached to the protease and the other peptide product diffuses away. In the second 
step the acyl-intermediate is deacylated to restore the catalytic triad and to release the second 
peptide product. This step also proceeds through a tetrahedral transition state with H2O in the role of 
the NH2-group of the peptide. A nucleophilic attack by the hydroxyl group of a water molecule that is 
hydrogen bonded to His57 releases the carboxylic acid product restoring the protease in its initial 
state (Hedstrom, 2002). 
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Fig. 1.2 The mechanism of chymotrypsin 
The catalytic cycle is schematically shown. Acylation includes extraction of a proton from Ser195 by His57, attack of the scissile peptide 
bond by Ser195 and formation of the tetrahedral intermediate. Donation of a proton to the peptide nitrogen from His57 and cleavage of 
the peptide bond releases the first product. Deacylation includes the attack of the acyl-enzyme intermediate by H2O that donates a proton 
to His57. The remaining OH attacks the acyl carbon forming a second tetrahedral transition state. His57 donates a proton to the Ser195 
oxygen. The ester bond is cleaved and the second product is released. The figure is adapted from Geoffrey M. Coopers “The Cell”, 2nd 
edition 2000. 
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Fig. 1.3 Contribution of the oxyanion hole to the enzymatic mechanism of chymotrypsin  
During the formation of the tetrahedral intermediate, the carbonyl oxygen of the substrate obtains a partial negative charge and moves to 
the oxyanion hole. Two hydrogen bonds are formed in the oxyanion hole that stabilise the tetrahedral transition state. The picture was 
adapted from Dr. Jakubowski’s Biochemistry online. 
 
1.3.2 S1 specificity pocket 
The binding site for a polypeptide substrate consists of a series of subsites across the surface of the 
enzyme. However, very often only the primary binding pocket, also called the S1 specificity pocket is 
well defined. The specificity of the pocket depends on its depth as well as on the electrostatic 
properties of the residues forming the surface of the pocket. Digestive proteases such as try sin, 
chemotropism or lactase have very similar three dimensional structures but show different substrate 
specificity. They cleave their substrates after positively charged, bulky aromatic or small uncharged 
side chains respectively (Blow 1997; Edstrom et al. 2002). Studies on protease specificity usually 
focused on the P1/S1 interaction (based on the nomenclature of Schuster and Berger (1967). P1 
(peptide 1) represents the first residue of the N-terminal side of the scissile bond. The subsites on the 
protease, for example S1 (subside 1) interact with the substrate. Three residues determine the 
different preferences. In chymotrypsin, residues 189-192, 214-216 and 224-228 form the S1 pocket 
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and the specificity is determined by residues Ser189, Gly216 and Gly226 (Perona and Craik 1995; 
Czapinska and Otlewski 1999). These three residues create a deep hydrophobic pocket that binds to 
hydrophobic residues of the substrate. In contrast, in trypsin Asp189, Gly216 and Gly226 create a 
negatively charged specificity pocket that interacts with Arg or Lys side chains at the P1 site of the 
substrate (Huber et al. 1974, Hedstrom et al. 2002). Elastase prefers small uncharged residues as 
Val216 and Thr226 line the specificity pocket (Shotton and Watson, 1969, Hedstrom et al. 2002). 
Besides the S1 specificity pocket the substrate interacts with additional binding pockets. Mainly the 
main chain of residues 214-216 interact with the backbone of residues P1 to P3 of the substrate 
forming an antiparallel beta sheet (Hedstrom et al. 2002). Additional structural features that 
generate substrate specificity and modulate enzyme activity are ions such as Na+ and Ca2+, surface 
insertion loops and exosites that are linked to the polypeptide binding sites and active site (DiCera 
and Krem 2003). 
1.4 PDZ domains 
PDZ domains are protein-protein interaction modules and are present in all kingdoms of life from 
bacteria to vertebrates. The name PDZ domain (also known as GLGF repeat) derives from the first 
three identified PDZ domain containing proteins: the postsynaptic protein PSD-95, the Drosophila 
disc large tumor suppressor, Dlg and the tight junction protein ZO-1 (reviewed in Hung et al. 2002). 
PDZ domains are found within diverse multi-domain proteins and recognize mainly the carboxy 
termini of their target proteins (Beebe et al. 2000). They often play important roles in organizing and 
linking multi-protein networks involved in signalling pathways and subcellular transports (Milev et al. 
2007). Beside binding substrates through their C-termini also internal PDZ binding motifs exist which 
mimic a C-terminus (Harris et al. 2001). PDZ domains are composed of 90 to 120 amino acids and 
share a common three-dimensional structure (Fig. 1.4). The fold comprises six "ß-strands ("ßA – "ßF), 
forming two antiparallel sheets stacked onto each other with two α helices (αA and αB) packed 
against the edges of the ß sandwich to build the hydrophobic core (Milev et al. 2007). The peptide 
binding site is on the opposite side to the closely to each other located N- and C-termini (Harris et al. 
2001). Although there are only small variations in the structure of different PDZ domains they show 
different specificity towards substrates. A nomenclature to describe the last few C-terminal amino 
acids bound by a PDZ domain has been developed. The C-terminal residue of the substrate is referred 
to as the P0 residue, negatively counting towards the N-terminus for subsequent residues. Based on 
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the interaction with the -2 position three classes of PDZ domains have been described. Residues at -1 
and -3 are supposed to mediate the fine tuning of the binding (Milev et al. 2007, Songyang et al. 
1997). Peptide binding to a PDZ domain is defined by two important features. First, peptides bind in 
an extended groove on the surface between ßB and αB forming an additional, antiparallel ß-strand 
(Fig. 1.4). Second, the C-terminal residue of the ligand points into a deep hydrophobic pocket, built 
by conserved residues (Doyle et al. 1996). The highly conserved GLGF loop motif which binds the 
COOH-terminus of the peptide and a positively charged residue (arginine or lysine) are important 
features for binding C-terminal peptides in a canonical fashion (Harris et al. 2001).  
 
Fig. 1.4 Canonical peptide binding mode 
A) Ribbon diagram of the third PDZ domain from the synaptic protein PSD-95 in complex with a peptide ligand (Doyle et al., 1996). Peptides 
bind in the groove between ßB and αB forming an additional antiparallel ß-sheet (shown in magenta). B) Chemical interactions involved in 
peptide binding. The PDZ domain is coloured in green and the ligand in purple. Hydrogen bonds are indicated by dotted lines coloured in 
cyan. The Protein Data Bank entry code is 1BE9. 
 
In addition several PDZ domains were identified which bind internal recognition motifs (Hillier et al. 
1999, Harris et al. 2001). Here the binding does not depend on recognition of a typical carboxyl-
terminal motif but the domains interact in a linear head-to-tail fashion (Hillier et al. 1999). One 
example is the PDZ domain of neuronal nitric oxide synthase (nNOS) which can heterodimerize with 
the PDZ domain of postsynaptic density protein 95 (PSD95) by mimicking a peptide ligand which 
binds into the peptide binding groove of PSD95, except that a sharp ß-turn replaces the normally 
required carboxyl terminus (Hillier et al. 1999). This can explain how PDZ domains participate to 
assemble protein networks. Identifying the substrate specificity of a particular PDZ domain can shed 
light on its distinct binding behaviour and help to find physiological substrates to understand its 
distinct function. 
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1.5 The HtrA-family of serine proteases 
The HtrA (high temperature requirement) family represents a class of oligomeric serine proteases. 
The defining feature of the over 180 family members is the combination of a catalytic domain with 
one or more C-terminal PDZ domains (Clausen et al. 2002) (Fig. 1.5). Some members of this family 
possess additional N-terminal domains, such as transmembrane or insulin-like growth factor-binding 
domains (IGFBP) (Kim and Kim 2005). Functionally, HtrAs monitor protein homeostasis in the cell. 
Prokaryotic HtrAs underlie processes involved in tolerance against various folding stresses and 
pathogenicity (Jones et al. 2001, Cortes et al. 2002, Mo et al. 2006). The four human homologues are 
suggested to be involved in the onset of diseases related to deficient protein quality control including 
arthritis, cancer, ageing, Alzheimer´s or Parkinson´s disease (Clausen et al. 2002, Grau et al. 2005 and 
2006, Nie et al. 2005, Plun-Favreau et al. 2007). The cellular localization of HtrAs is connected to 
extracytoplasmic compartments such as the periplasm in Gram-negative bacteria or membranes in 
Gram-positive organisms. In eukaryotes HtrA proteases were found in the extracellular matrix, 
mitochondria and chloroplasts (Huesgen et al. 2006, Zurawa-Janicka et al. 2007, Vande Walle et al. 
2008). 
HtrA1 H. sapiens
HtrA2 H.sapiens
HtrA3 H.sapiens
HtrA4 H.sapiens
DegP E.coli
DegS E.coli
Deg1 A.thaliana
HtrA T.maritima
Kazal inhibitory domain
signal sequence IGF binding domain     
transmembrane domain
Protease                         PDZ1          PDZ2
458
458
436
445
448
355
437
459
 
Fig. 1.5 Domain architecture of the HtrA family of serine proteases 
Schematic representation of the domain organization of selected HtrAs. The protease domain is colored in green, PDZ1 and PDZ2 in 
orange. The N-terminal segments contain a signal sequences (olive), a transmembrane domain (red), an insulin-like growth factor (IGF) 
binding domain (violet) or a Kazal-like inhibitory domain (light blue). The amino acid lengths are indicated. Figure adapted from Clausen et 
al. 2002. 
 
Another interesting feature of the HtrA proteins is that protease activity can be reversibly switched 
on and off by the novel mechanism of reversible zymogen activation (Ehrmann et al. 2004). 
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1.5.1 Family of bacterial HtrAs 
Three HtrA proteins, DegP, DegQ and DegS, have been identified in E. coli. DegP and DegS have 
become well understood in the last years whereas DegQ is less well understood. DegP (also named 
HtrA or protease Do) was discovered more than 25 years ago, when Goldberg and co-workers 
systematically analysed the proteases in E. coli (Swamy et al. 1983). DegP is synthesized as a 
precursor protein with an N-terminal signal peptide that targets the protease to the periplasm 
(Pallen and Wren 1997). DegP was identified as a heat-shock protein and transcription of its gene is 
regulated by both σE and Cpx pathways in response to stress due to unfolded proteins in the cell 
envelope (Erickson and Gross 1989, Danese et al. 1995). Biochemical data shows that the protease 
recognizes denatured or unfolded proteins and that it exhibits strong preference for cleavage after 
small hydrophobic residues like valine or isoleucine (Kolmar et al. 1996). Based on these studies it 
was proposed that DegP degrades misfolded proteins in the periplasm reducing damage. DegP was 
furthermore shown to display chaperone activity additionally to its digestive properties (Spiess et al. 
1999). The switch between these two functions is mediated by temperature: the chaperone activity 
is present at low temperatures (28°C) whereas the protease activity is most apparent at elevated 
temperatures (42°C) (Spiess et al. 1999). The large variety of substrates indicates that DegP is a key 
factor controlling protein fate in the cell envelope. Besides this physiological impact, DegP represents 
the first well-studied protein quality control factor that acts in an ATP-independent manner. Like 
DegP, DegQ is located in the periplasm of E. coli and shows similar substrate specificity as DegP 
(Kolmar et al. 1996). It is suggested to functionally substitute for DegP if it is over expressed in E. coli 
(Waller et al. 1996). That is supported by the fact that DegQ can complement the temperature 
sensitivity of degP null mutants (Waller et al. 1996). 
DegS is homologous to DegP and DegQ but differs in substrate specificity, oligomeric state and 
function. DegS has an N-terminal transmembrane segment and is localized in the inner membrane of 
E. coli. It has a trimeric structure with the active sites surface exposed (Ades et al. 1999, Alba et al. 
2002). In the latent state, the active site of DegS is present in an inactive conformation, in which 
substrate binding as well as catalysis is prevented (Wilken et al. 2004). After binding of stress 
peptides to its PDZ domains DegS is activated and cleaves the antisigma factor RseA at one specific 
position (Hasselblatt et al. 2007). Cleavage of RseA leads to the onset of a proteolytic cascade which 
causes the expression of several factors dealing with protein folding stress in the periplasm 
(Hasselblatt et al. 2007).  
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1.5.2 Family of human HtrAs 
The mammalian HtrA family of serine proteases is, like the other family members defined by a 
characteristic trypsin-like serine protease domain and one or two C-terminal PDZ domains. Four 
mammalian HtrA proteins have been identified to date, HtrA1–4. In analogy to their bacterial 
homologues, it seems likely that the human HtrA proteases also function in protein quality control 
(Maurizi 2002, Gray et al. 2000). Protein quality control involves protein diagnosis, stress response, 
protein repair and degradation. The bacterial members of the HtrA family are involved in most of 
these tasks in the bacterial periplasm. A specific system for extracelluar stress response in mammals 
has yet to be identified and therefore the potential involvement of human HtrA proteases in protein 
quality control (Grau et al. 2005) represents an interesting target. 
The four human family members can be divided into two groups mainly based on their domain 
architecture. HtrA2 possesses a transmembrane anchor and a large section of the N-terminus is 
removed during maturation. In contrast, the N-termini of HtrA1, 3 and 4 contain predicted signal 
sequences as well as domains that are known as insulin-like growth factor binding protein (IGFBP) 
and protease inhibitor domains (Fig. 1.5). Initial evidence suggests that stress response pathways 
might be involved in their regulation. HtrA1, 2 and 3 are better understood meanwhile and are 
discussed below. In contrast HtrA4 is not characterized so far. 
1.5.3 HtrA1 
HtrA1 (also called PRSS11) is a ubiquitously expressed serine protease which contains a signal 
sequence for secretion to the ECM, an insulin-like growth factor binding protein domain (IGFBP), and 
a Kazal-type serine protease inhibitor domain in addition to the serine protease domain and one C-
terminal PDZ domain (Clausen et al. 2002).  
The HtrA1 gene (PRSS11) was initially identified as being expressed in human fibroblasts but not after 
transformation with SV40 (simian virus) (Zumbrunn et al. 1996). Studies indicate that PRSS11 mRNA 
is either absent or significantly downregulated in several types of cancer e.g. in ovarian cancer 
(Shridhar et al. 2002, Chien et al. 2004), leukaemia, Burkitt's lymphoma (Nie et al. 2003), melanomas 
(Baldi et al. 2002) and mesotheliomas (Baldi et al. 2008). In addition, overexpression of HtrA1 
inhibited proliferation in vitro and tumor growth in vivo (Baldi et al. 2002). These results suggest 
HtrA1 having a tumor suppressor function. A tumor suppressor phenotype of a protease would be 
novel as so far this function was mainly attributed to protease inhibitors. 
Introduction      24 
HtrA1 was also shown to influence tumor response to chemotherapy by modulating chemotherapy-
induced cytotoxicity. Downregulation of HtrA1 attenuated cisplatin- and paclitaxel-induced 
cytotoxicity, while forced expression of HtrA1 enhanced cisplatin- and paclitaxel-induced cytotoxicity 
(Chien et al. 2006). Therefore HtrA1 is suggested to be a potential prognostic factor to measure the 
success of chemotherapies (Chien et al. 2006).  
HtrA1 expression is not induced by heat shock (in contrast to HtrA2) but could be regulated by a 
more general stress pathway. This notion is supported by upregulation of HtrA1 during osteo- (Hu et 
al. 1998, Chamberland et al. 2009) and rheumatoid arthritis (Grau et al. 2005), ageing (Ly et al. 2000) 
and Duchenne muscular dystrophy (Bakay et al. 2002). As a secreted protease, HtrA1 is likely to be 
involved in the degradation of extracellular matrix proteins, which could be important for both 
arthritis and tumor progression and invasion. Several recent reports describe e.g. the role of HrA1 in 
arthritis as HtrA1 contributes to degrading cartilage (Grau et al. 2006, Chamberland et al. 2009). 
Fibronectin from synovial liquids could be identified as a HtrA1 substrate and the treatment with 
HtrA1 leads to the expression of MMP1 and MMP3 implicating a role of HtrA1 in degradation of the 
ECM and that HtrA1 acts as a critical protease involved in proteoglycan turnover and cartilage 
degradation during degenerative joint disease (Grau et al. 2006). Recently it was shown by 
Chamberland et al. (2009) that aggrecan, a proteoglycan and major structural component of 
cartilage, is degraded by HtrA1 and that the proteoglycan content is dramatically reduced by HtrA1 
overexpression. Furthermore a genetic variation at the HTRA1 gene promoter locus is associated 
with spinal disc degeneration, suggesting once more an involvement of the htrA1 gene in 
osteoarthritis (Urano et al. 2010).  
HtrA1 is moreover degrading APP and APP-fragments like Aß and co-localizes with Aß plaques in the 
human brain (Grau et al. 2005) implicating a role of HtrA1 in Alzheimer´s disease.  
The existence of a single nucleotide polymorphism (SNPs) in the promoter region of the htrA1 gene 
(rs11200638) is a major genetic risk factor for wet age-related macular degeneration (AMD) (Dewan 
et al. 2006, Yang et al. 2006). The wet form of AMD is characterized by the formation of new blood 
vessels beneath the retina and therefore the irreversible loss of vision. The allele with the SNP is 
associated with an increased mRNA- and protein expression of HtrA1 (Yang et al. 2006). Recently, 
recombinant HtrA1 was shown to cleave RPE (retinal pigmented epithelium) secreted proteins like 
clusterin and fibromodulin which are involved in the regulation of the complement pathway and like 
alpha 2 macroglobulin and ADAM9 which are involved in amyloid deposition (An et al. 2010). 
There is also evidence that HtrA1 is involved in the TGFß signalling pathway. The expression of HtrA1 
during mouse embryonic development is restricted to tissues which are depending on the pathway 
during differentiation. Furthermore it was shown that HtrA1 binds to several TGFß-family proteins 
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like Bmp4, Gdf5 or activin, inhibiting the signalling mediated by these factors (Oka et al. 2004). 
Patients with CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy) show mutations in the htrA1 gene which leads to the synthesis of a protein 
that is less active and (therefore) less potent to inhibit the TGFß signalling pathway (Hara et al. 2009). 
These facts support the role of HtrA1 in the TGFß signalling pathway. 
During pregnancy the expression of HtrA1 is regulated dynamically displaying low expression levels in 
the first trimester and strong increased expression in the third trimester (De Luca et al. 2004). This 
expression pattern of HtrA1 in human placentas strongly implicates a role for HtrA1 in placental 
development and function. Moreover, on the basis of its subcellular distribution it was postulated 
that HtrA1 acts on different targets, such as intracellular growth factors or extracellular matrix 
proteins, to favor the correct formation and function of the placenta (De Luca et al. 2004).  
HtrA1 was also shown to cleave IGFBP-5, a factor which binds to IGFI and II thereby regulating the 
amount of these growth factors (Hue et al. 2005). Factors that alter IGFBP affinity have the capacity 
to regulate IGF actions. So far, it is not understood how cleavage of IGFBP-5 by HtrA1 alters the 
activity of IGFBP-5. 
Recently it was reported that human HtrA1 is a microtubule-associated protein and modulates 
microtubule stability and cell motility (Chien et al. 2009). It was shown that HtrA1 binds to 
microtubules via its PDZ domain, that is co-sediments with α- and ß-tubulin and that both proteins 
are a substrate for HtrA1 implicating a role in MT organization associated with cell migration (Chien 
et al. 2009). 
1.5.4 HtrA2 
In contrast to its paralogs HtrA1, 3 and 4, HtrA2/Omi contains a mitochondrial localization signal and 
is present in the mitochondrial intermembrane space (IMS). It is expressed as a 49-kDa proenzyme 
that is targeted to the mitochondrial IMS (Hedge et al. 2002, Martins et al. 2002) although a fraction 
of the endogenous HtrA2/Omi protein pool has been detected in the nucleus of resting cells (Martins 
et al. 2002, Gray et al. 2000, Kuninaka et al. 2007). HtrA2 is anchored via its transmembrane domain 
to the mitochondrial inner membrane, where it undergoes proteolytic maturation. The fully 
processed protein lacks the first 133 amino acids and exposes an N-terminal inhibitor of apoptosis 
protein (IAP)-binding motif (IBM). The motif is related to those found in the Drosophila IAP inhibitors 
Reaper, Hid and Grim and the mammalian IAP antagonist Smac/DIABLO (Hedge et al. 2002, Martins 
et al. 2002). If autodegradation or cleavage by another protease is required for maturation is still 
under discussion.  
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Protein levels of HtrA2 were shown to be upregulated several times after heat shock and after 
induction of the unfolded protein response induced by tunicamycin treatment (Gray et al. 2000). 
Several reports describe a regulatory function of the processed form of HtrA2 in apoptosis, a process 
that is necessary to remove excess, damaged or infected cells (Hegde et al. 2002, Martins et al. 2002, 
Suzuki et al. 2001, Van Loo et al. 2002, Verhagen et al. 2002). Nuclear DNA damage, death receptor 
activation and numerous other apoptotic insults trigger the translocation of the mature protease into 
the cytosol, where it contributes to apoptosis through both caspase-dependent and -independent 
mechanisms. The substrates of HtrA2 are proteins involved in apoptosis as well as inhibitors of 
apoptosis (IAPs) (Suzuki et al. 2004, Hedge et al. 2002, Martins et al. 2002). 
Evidence is present that HtrA2 is additionally involved in neurodegenerative disorders like 
Parkinson´s or Alzheimer´s disease. Two single nucleotide polymorphisms in the HtrA2/Omi gene 
cause missense mutations (A141S and G399S) and affect the enzymatic activity of the protease. They 
have been associated with the development of Parkinson’s disease in humans (Strauss et al. 2005). It 
was furthermore shown that the proteolytic activity of HtrA2 is regulated by PINK, a kinase 
associated with Parkinson s disease (Plu-Favreau et al. 2007). Additionally, HtrA2 was identified in a 
yeast-two-hybrid screen to bind to presenilin-2 and cleaving APP, implicating a role for HtrA2 in 
Alzheimer´s disease (Gupta et al. 2004, Park et al. 2006). Recent studies indicate that HtrA2 interacts 
with different proteins to maintain homeostasis of mitochondria (Dagda et al. 2009). 
The crystal structure of the maturated form of HtrA2 was solved in 2002 by Li et al. and is discussed 
in chapter 1.62. 
1.5.5 HtrA3 
HtrA3 shows 59% identity and 84% similarity to HtrA1 and shows the same domain architecture (Fig. 
1.5). In addition, the expression profile of HtrA3 in embryonic mouse tissues is similar to the 
expression profile of HtrA1 (Oka et al. 2004) and as HtrA1, HtrA3 also binds to several TGFß-like 
proteins inhibiting the signalling of Bmp4 and Bmp2 (Oka et al. 2004). HtrA3 is as well capable of 
cleaving ß-casein and some ECM-proteoglycans (Tocharus et al. 2004). Together these facts suggest 
that HtrA3 and HtrA1 fullfil overlapping tasks and have similar functions. 
The expression of HtrA3 is upregulated during development of mouse or human placenta (Nie et al. 
2006), but the physiological role is not yet understood. Recent studies about the expression levels of 
HtrA3 in ovaries of rats implicate that the protease is important for the development of this organ as 
well as its differentiation (Bowden et al. 2009). 
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HtrA3 mRNA levels are downregulated during progression of endometrial cancer (Bowden et al. 
2006). Thus, a decreased expression level of HtrA3 might be important for the development of 
cancer. Recent results suggest that similar to HtrA2, HtrA3 is located to the mitochondria and is 
released by treatment with drugs against lung cancer (Beleford et al. 2010). Thus, it is suggested to 
be a mitochondrial cell death factor whose serine protease function may be crucial to modulate 
etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines (Beleford et al. 2010). 
1.6 Serine protease structures of the HtrA family 
So far, five crystal structures are known for members of the HtrA family. These include the structure 
of human HtrA2/Omi (Li et al. 2002), the bacterial members DegP (Krojer et al. 2002, Krojer et al. 
2008) and DegS (Wilken et al. 2004, Hasselblatt et al. 2007) and of HtrA from M. tuberculosis 
(Mohamedmohaideen et al. 2008). The structure of the protease domain of HtrA from T. maritima 
(Kim et al. 2003) and of the PDZ domain of human HtrA3 (Runyon et al. 2007) have been furthermore 
solved. 
All known structures have in common that the functional unit appears to be a trimer, which is 
stabilised by residues of the protease domains. The protease domain adopts a chymotrypsin like fold 
with two antiparallel ß-barrels, each containing six ß-strands. The catalytic triad is composed of 
histidine, aspartate and serine. The PDZ domains are mobile elements; they act as molecular 
gatekeepers of the proteolytic chamber (DegP) or regulators of proteolytic activity (DegS, and 
HtrA2/Omi). 
1.6.1 Crystal structures of bacterial DegP  
Two crystal structures are available of DegP. The first crystal structure shows the protein in the 
inactive conformation. DegP is arranged as a hexamer composed of two stacked trimers forming an 
inner cavity (Fig. 1.6) (Krojer et al. 2002). The active sites of the protease are located in the inner 
cavity and are accessible only from the side (Fig. 1.6). The chamber is lined with hydrophobic patches 
that might constitute the substrate binding sites for non native polypeptides. The PDZ domains are 
highly flexible and form the side walls that restrict access to the active sites. In the same crystal two 
different conformations of DegP were found regarding the PDZ domains. In the so called ´open state´ 
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they protrude outwards creating a lateral passage with a freely accessible inner cavity while in the 
´closed state´ they close the entrances to the inner cavity (Fig. 1.6).  
The fact that regarding the PDZ domains two conformations were found could imply the following 
roles for the PDZ domains. First they are responsible for substrate binding and second for the 
translocation of the substrate into the inner chamber (Clausen et al. 2002, Krojer et al. 2002). 
Although the PDZ domains do not mediate the essential hexameric interactions in the ´open state´, 
the PDZ2 domains have been demonstrated to be indispensable for the hexamer formation in 
solution (Sassoon et al. 1999, Iwanczyk et al.  2007).  
Protease                      PDZ1  PDZ2
 
Fig. 1.6 Open and closed state of the DegP hexamer 
Side view of DegP hexamer in two states: ‘open state’ (left) and ‘closed state’ (right). Trimeric rings of the protease domain (grey) are 
connected by ‘loop LA pillars’ by forming an inter-subunit β-sheet (blue). PDZ domains are depicted in red (PDZ1) and yellow (PDZ2). The 
PDZ2 domains of the ‘open state´ were too flexible to be included in the model. The images of the structures were produced using PyMOL 
(DeLano 2002). 
 
Dimerization of the two trimeric rings is mediated by the interactions between loops LA from 
opposite trimers protruding into the active sites of the opposite trimer (Fig. 1.7). Loop LA* interacts 
with the active site loops L1 and L2 thereby distorting the active site meaning that proper adjustment 
of the catalytic triad and formation of the oxyanion hole is prevented (Krojer et al. 2002). In summary 
the hexameric structure of DegP shows a proteolytically inactive conformation and could thus 
represent a resting state of the protease/chaperone. 
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Fig. 1.7 DegP hexamer in the inactive conformation 
Loop LA (LA*) protrudes into the active site of the opposite monomer and distorts the conformation of the active site loops L1 and L2. 
Active site residues are depicted in ball and stick representation. An inactive Ser210Ala mutant was used for crystallization. PDB entry code 
for DegP: 1ky9 (Krojer, Garrido-Franco et al. 2002). The images of the structures were produced using PyMOL (DeLano 2002).  
 
Upon substrate binding DegP transforms from a hexamer into 12-meric and 24-meric multimers which show 
the catalytically active conformation (Krojer et al. 2008). In the crystal structure of the DegP 24mer (Krojer et 
al. 2008) eight trimers are located at the vertices of an octahedron. Figure 1.8 shows the overall structure of 
the DegP 24mer. In contrast to the structure of the DegP hexamer both PDZ domains are well defined and part 
of the model. The 24mer has a molecular mass of 1.13 MDa with an impressive cavity volume roughly 8-fold 
that of the bacterial chaperone GroEL (Krojer et al. 2008).  
Protease                     PDZ1   PDZ2
110 Å
 
Fig. 1.8 Overall structure of the DegP 24mer 
The DegP 24mer is shown in three different orientations along the molecular four-fold, three-fold and two-fold axes. The inner cavity has a 
diameter of 110 Å. PDZ domain1 is coloured in red, PDZ domain 2 in yellow. PDB entry code for DegP: 3cs0. The images of the structures 
were produced using PyMOL (DeLano 2002) and adapted from Krojer et al. 2008. 
 
These data indicate that by transforming from the hexamer into the 24mer the enzyme transforms 
from the inactive into the active conformation. Loop LA, which in the inactive conformation interacts 
with the active site of the neighbouring monomer and therefore distorts the active site by interacting 
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with loops L1 and L2, is now extracted and loop L1 and L2 are oriented to set up a functional 
proteolytic side (Fig.1.9) Therefore it has been suggested that the conversion from hexameric into 
higher oligomeric species is crucial for regulating the protease activity (Krojer et al. 2008).  
Protease                        PDZ1    PDZ2
 
Fig. 1.9 Conversion from the inactive into the active conformation in DegP24mer 
Active site residues are depicted in ball and stick representation. An inactive Ser210Ala mutant was used for crystallization. PDB entry code 
for DegP: 3cs0 (Krojer et al. 2008). Catalytically important loops are coloured in blue loop L1, in magenta loop L2, in orange loop L3 and in 
greed loop LD. The images of the structures were produced using PyMOL (DeLano 2002).  
 
In the structure of the 24mer (and the EM structure of the 12mer) additional density was found in 
the inner cavity. Further analysis of DegP oligomers identified this density as folded outer-membrane 
proteins like OmpA, OmpC and OmpF. Thus it can be concluded that the inner cavity serves 
antagonistic functions. The encapsulation of folded outer-membrane proteins protects these 
proteins from degradation in the periplasm and might be necessary to safely transfer them to their 
destination in the outer membrane of E. coli (Krojer et al. 2008). In contrast, misfolded proteins are 
degraded in the inner cavity. It was proposed that the mechanism of oligomerization upon substrate 
binding could also be true for the regulation of other HtrA family proteases. 
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1.6.2 Crystal structure of human HtrA2 
The only known crystal structure of a human family member is the one of HtrA2/Omi (Li et al. 2002). 
The structure was solved for the inactive (serine to alanine mutation) mature protein lacking the 133 
N-terminal residues. As the basic building block of all family members is the trimer, also HtrA2 forms 
a pyramide shaped homotrimer. Contacts between the monomers are mediated exclusively by the 
protease domain (Li et al. 2002) (Fig. 1.10).  
Protease            PDZ
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Fig. 1.10 Crystal structure of human HtrA2/Omi 
The HtrA2/Omi forms a homotrimer, which is viewed along (left) or perpendicular to (right) the three-fold symmetry axis. Trimerization is 
mediated exclusively by the serine protease domain. On top of the trimer at the N-terminus the IAP (inhibitor of apoptosis-binding 
tetrapeptide) motif is shown. The PDZ domains are located opposite at the base. Figure was produced using PyMOL and adapted from Li et 
al. 2002. 
 
Unlike the other structures of bacterial DegP hexamer or DegS, the PDZ domains of HtrA2 do not 
protrude outwards, but are located on top of the protease domain thereby restricting access to the 
active site. It has been proposed that the PDZ domains regulate protease activity and modulate 
HtrA2-mediated cell death activity (Li et al. 2002). Figure 1.11 shows a proposed working model for 
HtrA2. 
Low activity
Binding to 
target protein
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Fig. 1.11 Activation of HtrA2 
Activation of HtrA2 is proposed to proceed by binding of a trimeric ligand to the PDZ domains. In the basal state the PDZ domains restrict 
access to the active site resulting in a low activity of HtrA2/Omi. Upon binding of the ligand the PDZ domains protrude outwards, opening 
up the active site an allowing entrance for substrates. HtrA2/Omi probably targets trimeric ligands such as the DISC because it functions as 
a homotrimer. Picture adapted from Li et al. 2002. 
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2 Aims 
The HtrA (high temperature requirement) family represents a new class of oligomeric serine 
proteases in which a catalytic domain is combined with one or more C-terminal PDZ (protein-protein 
interaction) domains. These proteins are widely conserved and found in most organisms from 
bacteria to mammals. The biological implications of only some bacterial HtrAs are known while the 
human HtrAs are not well characterised and their precise functions are not understood in detail. 
In this thesis, studies should be performed to obtain an understanding of the structural properties of 
HtrA1 and the regulation of its proteolytic activity.  
To access the structural properties of HtrA1 different deletion contructs of the proteolytic active and 
inactive form of HtrA1 were applied for crystallization. Crystallization and subsequent structure 
solution consist of several consecutive steps, beginning with the establishment of an efficient and 
reproducible protein purification procedure. After purification, the protein can be characterized by 
N-terminal sequencing, mass spectrometry, size-exclusion chromatography and dynamic light 
scattering in order to detect any unwanted post-translational modifications, to elucidate the 
molecular weight of the oligomer in solution and the homogeneity of the sample. The crystallization 
of the protein can be performed by employing the widely used sparse-matrix screening methods. 
After production of diffraction quality crystals, the crystal structure of HtrA1 can be solved by 
molecular replacement (MR). With the crystal structure of HtrA1, it should be possible to elucidate 
the organization of the oligomer, the structural determinants of the active site and the role of the 
PDZ domains.   
In the second part of the study, the development of an activity assay and the measurement of 
enzymatic activity of different deletion constructs is the main focus. Furthermore it shall be tried to 
find inhibitors, peptides and substrates to characterize their interaction with HtrA1 and to co-
crystallize them with HtrA1 in order to specify the regulations of enzymatic activity.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Chemicals and their suppliers 
antibiotics  Sigma 
crystallization kits Hampton Research  
Ni-NTA-agarose Qiagen 
Superdex-200 PHARMACIA 
further chemicals Merck, Fluka, Serva, Sigma 
3.1.2 Bacterial strains 
Tab. 3.1 Bacterial strains 
Strain Genotype Origin 
DH5α 
F-, supE44, ∆lacU169, [Φ80lacZ∆M15], 
hsdR17, recA1, endA1, gyrA96, thi-1, 
(res-, mod+), deoR (Hanahan 1983) 
 
 
CLC 198 MC4100 degP::Tn10  
One Shot® Chemically 
Competent E. coli Mach1 
F-
 
φ80(lacZ)ΔM15 ΔlacX74 hsdR(rK
-mK
+) 
ΔrecA1398 endA1 tonA nupG 
Invitrogen 
BL21 (DE3) (RIL) F
- ompT hsdSB(rB
- mB
-) gal dcm (DE3) Novagen 
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BL21-CodonPlus (DE3)-RIL 
E. coli  F- ompT hsdSB(rB
- mB
-)  dcm+  Tetr 
gal λ (DE3) endA The [argU ileY leuW 
CamR) 
Stratagene 
BL21 (DE3) Rosetta 
F- ompT hsdSB(rB
- mB
-) gal dcm  (DE3) 
pRARE1 (CamR) 
Novagen 
BL21 (DE3) Origami B 
F- ompT hsdSB(rB
- mB
-) gal dcm lacY1 
ahpC gor522:: Tn10 trxB (KanR, TetR) 
Novagen 
B834 F
- ompT hsdSB(rB
- mB
-) gal dcm met Novagen 
1 pRARE contains the tRNA genes argU, argW, ileX, glyT, leuW, proL, metT, thrT,tyrU, and thrU. The rare codons AGG, AGA, AUA, CUA, CCC, 
and GGA are supplemented. 
3.1.3 Plasmids and vectors 
Tab. 3.2 Plasmids 
Name  Genotype Reference / source Resistence 
pCS20 
pQE60 derivative with lac IQ, 
degP (C-terminal His6-tag)  
(Spiess et al. , 1999) amp 
pET 21d pBR322 derivative  Novagen amp 
pET 26b pBR322 derivative Novagen kan 
pCS21  
pQE60 derivative with lac IQ, 
degPS210A (C-terminal His6-tag) 
(Spiess et al.1999) amp  
pET32a pBR322 derivative Novagen amp 
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3.1.4 Oligonucleotides for Cloning 
All oligonucleotides were synthesized by Life Technologies. 
 
Tab. 3.3 Nucleotides for Cloning 
Name Nucelotidsequence 5´- 3´ 
Cloning  in pET 21d 
Fw: LT_HtrA1_Helix1_NcoI CATGCCATGGGGCAGGAAGATCCCAACAGTTTGCGCCATAA  
LT_HtrA1_Helix2_NcoI CATGCCATGGCAAAATATAACTTTATCGCGGACGTGGTGGA  
LT_HtrA1_SC_NcoI CATGCCATGGCACTGCAGCGCGGAGCCTGCGGCCAA  
Cloning  in pET 21d and pET 26b 
LT_HtrA1_dSS_4_NcoI CATG CCATGGCG CAG CTG TCC CGG GCC GGC CGC 
LT_deltamacHtrA1_XhoI CCG CTCGAGAGA TCT TGG GTC AAT TTC TTC GGG 
LT_HtrA1_Kazal_1_XhoI CCG CTCGAGTTG GCC GCA GGC TCC GCG CTG CAG GAC 
LT_HtrA1_Kazal_2_XhoI  CCG CTCGAGCTG CCC TTG GCC GCA GGC TCC GCG 
LT_HtrA1_dSS_SG_NcoI  CATGCCATGGCACAGCTGTCCCGGGCCGGCCGCTCG 
LT_HtrA1_Kazalonly_NcoI CATG CCATGGTGCGG CGG CGC GCG CAG GCC GGC 
LT_HtrA1_IGFBPonly_XhoI CCG CTCGAGCGTGGCCGAGGCTGGCACCCCGAA GGG 
Cloning in pET 21d with Strep-tag 
LT_deltamacHtrA1_Strep  (NotI) ATAAGAAT GCGGCCGC TTA TTTTTCGAACTGCGGGTGGCT 
CCAAGCGCT (Strep) TGG GTC AAT TTC TTC GGG AAT CAC  
LT_HtrA1_Kazal_2_Strep (NotI)  ATAAGAATGCGGCCGC TTA TTTTTCGAACTGCGGGTGGCTC 
CAAGCGCT (Strep) CTG CCC TTG GCC GCA GGC TCC GCG 
Cloning in pET32a as Trx-fusion 
LT_HtrA1_ KpnI_Prec  CGG GGT ACC CTGGAAGTTCTGTTCCAGGGGCCC (Precs.) 
GATTCTGAGATG GCGCAGCTGTCCCGGGCCGGCCGC  
LT_deltamacHtrA1_BamHI  GGAGGA GGATCC AGATCTTGGGTCAATTTCTTCGGG 
LT_deltamacHtrA1_BamHI_stop GGACGC GGATCC TTAAGATCTTGGGTCAATTTCTTCGGG 
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LT_deltamacHtrA1_BamHI_corr GGACGC GGATCC TGGGTCAATTTCTTCGGGAATCAC 
LT_HtrA1_Kazal2_BamHI  GGA CGC GGATCC CTG CCC TTG GCC GCA GGC TCC GCG 
LT_HtrA1_Kazal2_BamHI_stop GGA CGC GGATCC TTA CTG CCC TTG GCCGCAGGC TCCGCG 
LT_deltamacHtrA1_XhoI_stop CCG CTCGAG TTA AGA TCT TGG GTC AAT TTC TTC GGG 
LT_HtrA1_Kazal_2_XhoI_stop  CCG CTCGAG TTA CTG CCC TTG GCC GCA GGC TCC GCG 
Cloning in PDDII83 (Gal – TEV - myc vector) for yeast expression 
LT_Fw_Yeast_BamHI GGA CGC GGATCC ATG GCG CAGCTGTCCCGGGCCGGC CGC  
LT_ FL_Yeast_NotI ATAAGAAT GCGGCCGC TGGGTCAATTTCTTC GGGAATCAC 
LT_ Kazal2_Yeast_NotI ATAAGAATGCGGCCGC CTG CCC TTG GCC GCAGGCTCC GCG 
LT_ FL_Yeast_His_NotI ATAAGAAT GCGGCCGC TTA GTGGTGGTGGTGGTGGTG (His-Tag) 
TGGGTCAATTTCTTC GGGAATCAC  
LT_ Kazal2_Yeast_His_NotI  ATAAGAAT GCGGCCGC TTA GTGGTGGTGGTGGTGGTG (His-Tag) CCC 
TTG GCC GCA GGC TCC GCG 
Cloning in pET 21d with SUMO-taq 
LT_HtrA1_dSS_4_NcoI  CATG CCATGG CG CAG CTG TCC CGG GCC GGC CGC 
LT_deltamacHtrA1_BamHI_stop GGA CGC GGATCC TTA AGA TCT TGG GTC AATTTCTTC GGG 
LT_HtrA1_Kazal2_BamHI_stop GGA CGC GGATCC TTA CTG CCC TTG GCCGCAGGCTCC GCG 
3.1.5 Media 
LB (Luria Bertani) medium:   10 g Bacto-tryptone  
5 g Yeast extract  
10 g NaCl  
made up to 1 l with H2O and autoclaved 
 
LB (Luria Bertani) Agar:    1 l LB medium 
     15 g Agar 
 
 
Materials and Methods          37 
 
NM-medium:    740 ml H2O  
100 ml 10x salts  
100 ml 10x amino acids  
60 ml 1 mg/ml seleno-DL-methionine  
autoclave H2O, then add the other sterile filtered  
 components 
 
10x salts:   1 M (NH4)2SO4    75 ml  
5 M NaCl     17 ml  
1 M MgSO4
     
10 ml  
1 M Glucose    200 ml  
1 mg/ml CaSO4 x 2H2O  10 ml  
Trace elements  10 ml    
10 mg/ml Thiamine   10 ml  
10 mg/ml Biotine   10 ml  
FeNH4(SO4)2
  
x 6H2O   1 ml (add before use)  
H2O     65 ml  
 
Trace elements:   10 mg/ml MnCl2  5 μl  
10 mg/ml CuSO4 x 5H2O  5 μl  
10 mg/ml Na2MoO4  5 μl  
10 mg/ml ZnSO4  5 μl  
made up to 50 ml with H2O 
  
10x amino acids:   H2O     274 ml  
1M K2HPO4   476 ml  
1M KH2PO4
    
220 ml  
Alanine    0.5 g  
Arginine    0.5 g  
Aspartate    0.5 g  
Aspartic acid    0.5 g 
Cysteine    0.5 g  
Glutamic acid    0.5 g  
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Glutamate    0.5 g  
Glycine    0.5 g  
Histidine    0.5 g  
Isoleucine    0.5 g  
Leucine    0.5 g  
Lysine     0.5 g  
Proline     0.5 g  
Serine     0.5 g  
Threonine    0.5 g  
Valine     0.5 g  
 
 
 Amino acids II:    H2O     28.5 ml  
Phenylalanine    0.5 g  
Tryptophan    0.5 g  
Tyrosine    0.5 g  
32% (v/v) HCl    1.5 ml 
3.1.6 Antibiotics 
Ampicillin: 50 mg/ml in H2O stock solution, stored at -20°C 
Kanamycin: 50 mg/ml in H2O stock solution, stored at -20°C 
Tetracyclin: 50 mg/ml in H2O stock solution, stored at -20°C 
3.1.7 Proteins and enzymes 
Tab. 3.4 Proteins and Enzymes for Cloning 
Protein/Enzyme Origin 
BSA (Bovine serum albumin) Sigma-Aldrich, München 
DNAseI Sigma-Aldrich, München 
CIP NEB 
T4 Ligase Roche 
Herculase Roche 
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Phusion High Fidelity Polymerase Finnzymes, NEB, Ipswich, MA, USA 
Restriction enzymes NEB, Ipswich, MA, USA 
3.1.8 Protein and nucleic acid standards 
Tab. 3.5 Protein- and Nucleic Acid Standards for SDS-PAGE and Agarosegels 
Standard Company 
FPLC Gelfiltration LMW&HMW Standard Bio-Rad, München 
BSA (Rinderserumalbumin) Sigma-Aldrich, München 
Prestained SDS-PAGE Standard Bio-Rad, München 
Unstained SDS-PAGE Standard Bio-Rad, München 
Quick-Load 2-Log DNA Ladder NEB, Ipswich MA, USA 
3.2 Methods 
3.2.1 Microbiological methods 
3.2.1.1 Sterilisation 
Media and solutions were sterilised by autoclaving. In the course of this, they were heated to 120°C 
with a pressure of 1 bar for 20 min. Heat sensitive solutions were sterile filtered with a 0.22 μm filter 
(Millipore).  
3.2.1.2 Growth conditions  
Liquid cultures were grown in Erlenmeyer flasks of appropriate size. In order to improve the oxygen 
supply, the flasks contained chicanes. The flasks were shaken at 180 rpm and incubated at a 
temperature of approx. 37°C. Recombinant ∆N-HtrA1 and HtrA1-prot (wild type and S328A mutant)
 
were expressed in E. coli BL21 (DE3) cells. Full length HtrA1 and NT-HtrA1 were expressed in E. coli 
Origami B cells (Novagen). All proteins contained a C-terminal His6-tag, the full length and NT-HtrA1 
protein additionally an N-terminal TrxA-tag and a His6-tag. The cells were grown in LB-medium with 
50 μg/ml ampicillin at 37°C until they reached an OD600 of 0.8 to 1.0 followed by induction with 500 
μM IPTG. Cells with full length protein or the N-terminal domain were grown for 3 hrs at 37°C, cells 
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with other constructs for 16 hrs at 28°C. E. coli B834 cells were used for the expression of ∆N-
HtrA1(SeMet) and treated the same way. 
3.2.1.3 Determination of the cell density in liquid cultures  
The cell density of liquid cultures was determined by measurement of the optical density in a 
photometer at a wavelength of 600 nm. LB media was used as a blank. 
3.2.1.4 Polymerase chain reaction (PCR) 
To PCR amplify DNA fragments (Mullis et al. 1992) an initial denaturation step at 95°C for 5 min, 
followed by 35 cycles of 10 sec denaturation,  20 sec annealing at 55°C to 60°C and 44 sec extension 
at 72°C was performed. Finally the reaction was heated to 72°C for 10 min and then cooled to 4°C. A 
typical pipetting scheme is given below (Tab. 3.6). 
 
Tab. 3.6 Pipetting scheme for PCR reaction 
Volume [µl] Component 
5 10x Herculase buffer 
5 dNTPs (jeweils 10 mM) 
0.5 Primer forward (10 µM) 
0.5 Primer reverse (10 µM) 
0.5 Herculase 
5 DMSO 
0.5 Template 
ad 50 µl H2O 
 
DMSO was used in every PCR reaction as the GC-rich region of the htrA1 gene had the potential to 
form secondary structures which could be relaxed by DMSO. The results of the PCR reaction were 
checked by agarose gel electrophoresis (3.2.1.6). 
3.2.1.5 Colony PCR 
To select for positive clons after transformation a colony PCR was performed. Per plate 3 to 5 
colonies were picked with a sterile pipette tip and directly pipette into a prepared PCR mixture.  
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Tab. 3.7 Colony PCR pipetting scheme 
Volume [µl] Component 
2.5 10x Thermo Pol-Puffer 
0.3 dNTP (10 mM each) 
0.5 Primer forward (10 µM) 
0.5 Primer reverse (10 µM) 
2.5 DMSO 
0.5 Taq-Polymerase 
ad 25 µl H2O 
 
PCR-program: 
1.   94°C 2 min 
2.   94°C 15 s 
3.   55°C 15 s 
4.   72°C 45 s 
5.   72°C 5 min 
 
For analysis of PCR products 5 µl are loaded to an agarose gel (3.2.1.6) to identify positive clons for 
plasmid mini preps (3.2.1.12). 
3.2.1.6 Agarose gel electrophoresis 
Agarose gel electrophoresis was employed to separate double-stranded DNA molecules according to 
their molecular mass after restriction enzyme digestion and to quickly determine the yield and purity 
of a DNA isolation or PCR reaction. The agarose concentration of the gel depends on the various sizes 
of the separating DNA fragments to be visualized; generally a 1% (w/v) solution was used. The 
agarose was dissolved in 1x TAE by heating in a microwave oven. Ethidium bromide was added to 
enable fluorescent visualization of the DNA fragments under UV light and the cooled (approx. 50°C) 
gel was poured into a gel casting form containing the gel comb. After cooling down, 1x TAE 
electrophoresis buffer was added to the buffer reservoirs until the gel was covered. The samples (1–
20 μl) were mixed with 1/10 of their volume with DNA loading buffer and subjected to 
electrophoresis for one hour at 70 V. Additionally, a DNA size-marker (Lambda Eco/Hind III) was co-
electrophoresed with the DNA samples to identify fragments between 500–22,000 bp. After 
electrophoresis, the DNA-intercalated ethidium bromide was detected under UV light at 302 nm.  
 
40 cycles 
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50x TAE-Puffer:   50 mM EDTA 
2 M Tris-Acetat, pH 8.0 
 
6x DNA-Probenpuffer:   30% (v/v) glycine 
0.25% (w/v) bromophenol blue 
0.025% (w/v) xylencyanole 
3.2.1.7 DNA isolation from agarose gels 
DNA gel extraction and PCR purification protocols were performed as described in “QIAquick Spin 
Handbook” using a microcentrifuge (July 2002), applying the QIAquick Gel Extraction Kit and 
QIAquick PCR Purification Kit. The purified DNA was eluted in 30–50 μl 1xTE buffer.  
3.2.1.8 Determination of DNA concentration 
The absorbance of the DNA samples at 260 nm was measured with a micro-volume UV-Vis 
spectrophotometer (Nanodrop 2000) and the concentration was calculated according to the Lambert 
Beer Law. The ratio of absorptions at 260 nm versus 280 nm is used to assess the purity of the 
sample with respect to protein contamination, since protein (in particular, the aromatic amino acids) 
tends to absorb at 280nm. Absorption at 230 nm can be caused by contamination by phenolate ion, 
thiocyanates, and other organic compounds. For a pure nucleic acid sample, the 260:230 ratio should 
be around 2. 
3.2.1.9 Restriction enzyme digestion, dephosphorylation, ligation 
Restriction digests were performed using the supplied buffers at recommended temperatures 
(Fermentas). Typically, 1-2 units of enzyme were used per 1 μg of DNA. To prepare the vectors for 
cloning, they were digested as described above. To avoid self-ligation and increase ligation efficiency, 
15 U calf intestinal phosphatase (CIP) was added for 1 h at 37°C to remove 5' phosphates of cut 
vector. After successful restriction digestion of the insert and the vector, both were purified by gel 
extraction (Gel Extraction Kit, Qiagen). To perform ligation insert and vector were mixed in a 3:1 
ratio, respectively. The reaction mix was incubated with 1 U T4 DNA ligase in the appropriate 10x 
buffer at 20°C for 2 hrs or left overnight at 4°C. DH5α cells were transformed and plated out for 
selection on LB plates.  
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3.2.1.10 Production of chemically competent E. coli cells 
Chemically competent B834 and Origami B cells were prepared using the following protocol. LB 
media containing the appropriate antibiotics was inoculated with a single colony and grown over 
night at 37°C. 50 ml LB media was inoculated the next day to an OD600 of 0.1 and grown till an OD600 
of 0.5. Cells were incubated 15 min on ice and centrifuged for 15 min at 4°C in a 50 ml falcon tube. 
The pellet was carefully resuspended in 1/3 cold RF I solution, incubated on ice for 15 min. and again 
centrifuged for 15 min at 4°C. Subsequently the pellet was resuspended in 1/12 RF II, incubated 15 
min on ice, aliquoted and frozen in liquid nitrogen. The cells were stored at -80°C. 
 
RF I: 100 mM RbCl, 50 mM MnCl2, 10 mM CaCl2, 30 mM potassium acetate, 15% glycerin, 
pH adjusted to 5.8 with acetic acid  
 
RF II: 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% glycerin 
  pH adjusted to 6.8 with NaOH   
  
3.2.1.11 Transformation of chemically competent E. coli cells 
The plasmids were cloned into DH5α cells during the cloning and selection procedures, whereas 
supercompetent BL21 (DE3) and Origami B cells were transformed for overexpression. Aliquots of 
cells (100 μl DH5α; 50 μl BL21 Star (DE3), 25 μl Origami B cells) were transformed with 1 μl of plasmid 
DNA and incubated on ice for 20 min before exposure to 42°C for 90 sec. After incubation for 1 min 
on ice 1 ml LB medium was added to the cells were incubated at 37°C for 1 h on a shaker (1200 rpm). 
Afterwards, they were either transferred into liquid LB media or plated on LB selective media 
containing the appropriate antibiotic and grown overnight at 37°C. 
3.2.1.12 Plasmid isolation 
Two different plasmid purification kits were employed. For low scale plasmid preparation, used for 
identifying colonies containing the correct plasmid, the Plasmid Mini kit (Qiagen) was used. After 
sequencing larger amounts of plasmid DNA of positive clons was needed for transformation, 
therefore plasmid purification was done using Plasmid Midi kit (Qiagen). For minipreps 5 ml, for 
midipreps 100 ml of LB media, containing 50 μg/ml ampicillin for selection was inoculated with a 
single bacterial colony of ampicillin resistant E. coli and incubated overnight at 37°C. Grown cells 
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were harvested by centrifugation (4000 rpm in Heraeus Multifuge 4 KR, 15 min for minipreps; 25 min 
for midipreps) and afterwards purified following the manufacturer‘s instructions according to the 
alkaline lysis method. Purified DNA was eluted in 50 μl TE buffer for minipreps and 200 μl TE buffer 
for midipreps. For storage the plasmid DNA was frozen at -20°C. For the determination of the yield of 
purified midiprep DNA the sample was 1:50 diluted and the concentration was measured by UV 
spectrophotometry at 260 nm (Ultrospec 3300 pro, Amersham Biosciences). The quality of the DNA 
was determined by calculating the ratio of the optical density at 260 nm and 280 nm.  
3.2.1.13 Cloning of full length HtrA1 and NT-HtrA1 
Full length protein and the N-terminus of HtrA1 (NT-HtrA1, residues 22 – 159) lacking the signal 
sequence (residues 1-21) were cloned in fusion with a thioredoxin A-tag (TrxA-tag) to support proper 
folding of HtrA1 which contains 18 cysteines in the N-terminal domain. TrxA contains in its active 
center a disulfide bond … The protein was cloned into a pET32a vector (Novagen) which provides the 
possibility to express the protein of interest in fusion with TrxA. The vector contains cleavage sites to 
cleave the tag with factor Xa and TEV. Instead HtrA1 was cloned with a PreScission cleavage site 
which was inserted by PCR with the forward primer. PreScission protease is described to be more 
efficient and more importantly does not require DTT for activity as e.g. TEV. In addition PreScission is 
a cysteine protease and therefore any impurity would not interfere in activity assays. HtrA1 was PCR 
amplified from pSG 7 and pSG 13 (SA mutant) and restriction sites for KpnI and XhoI were introduced 
by PCR as well as the PreScission cleavage site. The Tag is fused N-terminal and contains itself a C-
terminal His6 tag. HtrA1 was cloned either in frame or out of frame with a C-terminal His6-tag 
provided by the vector. 
 
Stop
XhoIKpnI
PreScission
ATGATG
His6 His6TrxA-tag HtrA1  
Fig. 3.1 Cloning strategy for full length HtrA1 in pET32a 
PET32a provides a TrxA-tag in frame with an C-terminal His-tag. Via PCR the gene of interest is amplified introducing a         C-terminal KpnI 
and a PreScission cleavage site and a N-terminal XhoI cleavage site. The PCR product is subsequently cloned into pET32a in frame with the 
TrxA-tag and a second N-terminal His-tag.   
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3.2.2 Biochemical methods 
3.2.2.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE)  
SDS-PAGE was used for the electrophoretic separation of proteins according to the method of 
Laemmli (Laemmli, 1970). The stacking and the separating gel were prepared as described below 
(table 3.8). Gels were poured in an apparatus for 8 minigels. The protein samples were mixed with 5 
μl of 2x sample buffer, boiled for 5 min and loaded onto the gel. The electrophoresis was performed 
at 110 to 200 V for about 60 min. Afterwards the gel could either be blotted (3.2.2.4) or stained with 
Coomassie brilliant blue (3.2.2.2).  
 
Tab. 3.8 Composition of polyacrylamid gels 
component separating gel (12.5%) stacking gel (5%) 
buffer A 37.5 ml - 
buffer B - 2.5 ml 
acrylamide stock 40 ml 8.3 ml 
H2O 21 ml 38.4 ml 
10% (w/v) SDS 1 ml 0.5 ml 
TEMED 80 μl 40 μl 
10% (w/v) APS 800 μl 400 μl 
 
 
Buffer A:    1 M Tris/HCl pH 8.8  
 
 
Buffer B:    2.5 M Tris/HCl pH 6.8  
 
 
Acrylamide stock:   30% (w/v) Acrylamide 0.8% (w/v) Bisacrylamide  
 
 
Sample buffer:    1.25 ml 2 M Tris/HCl, pH 6.8,  
3.2 ml Glycerol (87%)  
180 μl 2-Mercaptoethanol  
+ a few grains of bromophenolblue  
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0.8 g SDS  
filled with H2O to 10 ml  
Running buffer:   25 mM Tris/HCl  
200 mM Glycine  
0.1% (w/v) SDS  
pH 8.3  
 
2x SDS-Sample-buffer:  0.2 M Tris-HCl, pH 6,8 
8% (w/v) SDS 
40% (v/v) Glycerol 
0.04% (w/v) Bromophenol blue 
30 mM DTT 
3.2.2.2 Coomassie blue staining  
The polyacrylamide gels were stained by soaking in a staining solution and boiling for 20 sec in a 
microwave oven. Afterwards, the gels were gently shaken for 10min at RT. For destaining, the gels 
were transferred to a destaining solution and again boiled for several seconds and subsequently 
shaken for approximately one hour at RT. The destaining procedure was repeated until the gel was 
completely free of background stain.  
 
Staining solution:   2.5 g Coomassie brilliant blue R-250  
250 ml Ethanol  
80 ml acetic acid  
filled with H2O to 1 l  
 
 
Destaining solution:   250 ml ethanol  
80 ml acetic acid  
filled with H2O to 1 l  
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3.2.2.3 Determination of protein concentration  
Two distinct methods have been used in order to measure the protein concentration of a given 
sample. Note that concentrations measured by the Bradford method are given in mg/ml, whereas 
the concentrations determined by absorbance at 280nm are given in molar concentrations.  
 
a) Bradford protein assay  
For the determination of the protein concentration according to the method of Bradford (Stoscheck, 
1990) 795 μl H2O were mixed with 5 μl of protein solution and 200 μl of Bradford-solution (BioRad, 
Germany) in a plastic-cuvette. The Absorption of this mixture was measured in a photometer at a 
wavelength of 595nm against a blank solution containing 800 μl H2O and 200μl of Bradford-solution. 
The corresponding protein concentration was calculated from a calibration curve using BSA as a 
standard.  
 
b) Absorbance at 280 nm  
The Absorbance of a protein sample at 280 nm has been measured with a Nanodrop 2000 (Thermo 
Scientific). The concentration was calculated according to the Beer-Lambert relation: A = ε x c x d, 
where A is the absorption at 280 nm, ε is the molar absorbance coefficient, c the molar 
concentration of the protein solution and d is the cell length of the cuvette. The molar absorbance 
coefficient of HtrA1 has been calculated as described by Gill and von Hippel (Gill and Vonhippel, 
1989). The molar absorbance coefficient of full length HtrA1 is 11430 M-1 cm-1 assuming all cysteines 
residues appear as half and 10430 M-1 cm-1 assuming that no cysteine residues appear as half 
cysteines. The coefficient for ∆N-HtrA1 is 8940 M-1 cm-1, for HtrA1-prot 5840 M-1 cm-1. HtrA1 does not 
contain any tryptophan residues and it was shown that this can result in more than 10% error in the 
computed extinction coefficient.  
3.2.2.4 Electroblotting of proteins to PVDF membranes for N-terminal sequencing 
After SDS polyacrylamide gel electrophoresis proteins were transferred to a PVDF (polyvinylidene 
diflouride) membrane (Amersham Biosciences) for subsequent N-terminal sequencing or Western 
blots. Transfer was carried out at 100 mA till 25 V were reached for approx. 1.5 h using a semi-dry 
blotting apparatus at room temperature in transfer buffer. For N-terminal sequencing, the 
membrane was stained in staining solution for one minute and afterwards destained in water for 15 
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min. Then the membrane was air-dried so that the blotted bands became visible. They were cut for 
N-terminal sequencing. 
 
Transfer buffer:  50 mM Tris, 380 mM glycine, 0.1% SDS, 20% methanol 
Staining solution:  Amido black solution 
3.2.2.5 Western Blot 
After separating the proteins according to their molecular mass by SDS-PAGE (3.2.2.1) and 
electroblotting of the proteins to a PVDF membrane (3.2.2.4) the membrane was blocked with 
blocking solution for 1 h at RT or 4°C over night. The primary antibody antipenta-His (mouse) was 
diluted 1:1000 in antibody solution (3% BSA in TBS) and the blot was incubated with shaking over 
night at 4°C or 1 h at RT. After washing three times with TBST for 1 h, the secondary antibody, anti-
mouse HRPO (diluted 1:15000 in 5% milk powder in TBS) was incubated shaking for 2 hrs at 4°C. 
Thereafter the blot was washed three times with TBST and finally developed for horseradish 
peroxidase (HRPO) activity: The blot membrane was incubated for 1 min in a 1:1 solution of stable 
peroxide and Luminol/Enhancer (Super Signal West Pico Chemiluminescent substrate, Pierce). The 
excess reagent was drained off and the blot was transferred into a film cassette wrapped in plastic 
foil. The blot was overlaid with an autoradiographic film (Hyperfilm ECL, Amersham Biosciences) in a 
dark chamber and exposed for 2 sec up to 2 min. The film was afterwards developed in a developer.  
 
Blocking buffer:  3% BSA, 1 mM EDTA, 0.05% Tween 20, 1:1000 20% NaN3 
 
TBS(T):    10 mM Tris pH 7.5, 150 mM NaCl, (0.05% Tween 20) 
3.2.2.6 Lipid binding assay 
Lipid binding of ∆N-HtrA1 and HtrA1-prot was performed as follows. Brain lipid extracts (Sigma, Folch 
fraction I) were suspended in 140 mM NaCl, 50mM Hepes-NaOH pH 7.4 and stock solutions of 
1mg/ml or 4 mg/ml were made. The proteins with a concentration of 0.1 mg/ml were incubated for 
15 min at 37°C with lipid concentrations 0.02, 0.05, 0.1, 0.2, 0.5, 1.0, 1.5 and 2 mg/ml in a final assay 
volume of 100 μl. 20 μl were taken as loading control and the samples were centrifuged for 30 min at 
42´000 rpm and 4°C. After the supernatant was removed and the pellet had been resuspended with 
an equivalent volume of 80 μl buffer, 20 μl samples from supernatant, pellet and loading control 
were analysed by SDS–PAGE. 
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3.2.2.7 Purification of full length HtrA1, full length HtrA1S328A and NT-HtrA1 
After expression, cells were harvested by centrifugation (4000 rpm), resuspended in 100 ml of buffer 
A and 2 ml DNAse I (1 mg/ml) was added. Otherwise the pellet was too viscous to be resuspended. 
Subsequently the cells have been disrupted by sonication on ice. From this point on, all steps of 
protein purification were performed at 4°C. The lysate was centrifuged (19´000 rpm, 40 min) and the 
supernatant was loaded on a Ni-NTA column (Qiagen) equilibrated with buffer B. The column was 
washed with buffer B and subsequently with stepwise increasing imidazole concentrations, namely 
12% buffer C (30 mM imidazole) and 20% buffer C (50 mM imidazole) to remove unspecific bound 
proteins. HtrA1 was eluted with 60% (150 mM imidazole). Eluted fractions were analysed by SDS-
PAGE. Subsequently the protein was concentrated with a concentrator (Vivaspin, Amicon, cutoff 
50´000 kDa) and desalted with a PD 10 column in buffer B. The elution fraction was digested with 
PreScission protease (GE Healthcare) to remove the TrxA-tag over night at 4°C (1 unit protease pro 
100 μg protein). This step was not required for the wild type protein as it underwent self cleavage 
and thus the TrxA-tag was removed after NiNTA purification. After concentrating the protein to 2ml 
the sample was applied with 1ml/min to a Superdex 200 26/60 column (GE Healthcare) to separate 
the cleaved tag and the PreScission protease from HtrA1. Gelfiltration fractions (2 ml fractions) were 
combined according to their elution volumes for trimeric HtrA1 (≈ 160 ml). The purified protein was 
concentrated using Vivaspin concentrators (Vivaspin, cut-off 30 kDa) to approx. 4 mg/ml. HtrA1S328A 
was taken for crystallization.  
 
Buffer A:   100 mM NaH2PO4 pH 7.5  
300 mM NaCl  
 
Buffer B:   50 mM NaH2PO4 pH 7.5  
150 mM NaCl 
 
Buffer C:  50 mM NaH2PO4 pH 7.5 
150 mM NaCl, 250 mM Imidazole 
 
 Buffer D:   10 mM HEPES/NaOH pH 7.5 
    50 mM (NH4)2SO4  
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3.2.2.8 Purification of ∆N-HtrA1, ∆N-HtrA1S328A, HtrA1-prot and HtrA1-protS328A 
Cell were harvested, sonicated, centrifuged and purified with a NiNTA and SEC mainly as described 
for the full length protein. The buffers for NiNTA contained Tris instead of phosphate and additionally 
5 mM ß-Mercapthoethanol (ß-ME). The NiNTA column was washed only with 30 mM imidazole to 
remove unspecific bound proteins. After NiNTA, the protein was concentrated to 2 ml and loaded to 
a Superdex-200 prep grade column (GE Healthcare) equilibrated with buffer D. Fractions containing 
trimeric HtrA1 were combined and either concentrated to approx. 40 mg/ml for ∆N-HtrA1 or 20 mg / 
ml for HtrA1-prot or taken for methylation. 
 
Buffer E:  100 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM ß-ME 
 
Buffer F: 100 mM Tris/HCl pH 7.5, 150 mM NaCl, 5 mM ß-ME, 250 mM Imidazol 
3.2.2.9 Methylation 
Screening with commercially available screens which sample a wide range of crystallization space is 
the first choice when crystallizing proteins as in many cases this approach was described to be 
successful. Proteins which fail to crystallize can be chemically modified to facilitate crystallization. 
Surface engineering of proteins by chemical modification offers a radical approach to reduce surface 
entropy. Reductive lysine methylation is one of the possibilities and was described as a simple, 
inexpensive and efficient rescue strategy by Walter et al. 2006 for proteins which failed to crystallize. 
The effect of methylation on the physico-chemical properties of these proteins are complex as pI, 
solubility and oligomeric state can be influenced (Walter et al. 2006). 
Purified ∆N-HtrA1 protein (1 mg/ml) was incubated for 2 hrs with 20 μl 1 M ABC (Boran 
dimethylamine complex, Sigma) solution and 40 μl 1 M formaldehyde solution per mg protein on ice. 
After adding the same amount of ABC and formaldehyde solution the mixture was incubated again 
for 2 hrs. Finally 10 μl ABC solution was added and the protein was incubated for 20 hrs at 4°C. 
The methylation reaction was stopped by adding 1 ml of 1 M Tris-HCl (pH 8.8) and a second size 
exclusion chromatography on a Superdex-200 in buffer D to yield a homogeneous fraction. Finally, 
the protein was concentrated to 30-40 mg/ml with Vivaspin concentrators (Vivaspin, cutoff 30 kDa) 
and taken for crystallization or biochemical assays. 
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3.2.2.10 N-terminal sequencing  
For N-terminal sequencing the protein was loaded to an SDS-PAGE, separated and blotted to a PVDF 
membrane. The degradation band was cut and sended to Alphalyse in Denmark. The analysis was 
performed on an ABI Procise 494 sequencer. The procedure determines the amino acid sequence of 
proteins by Edman procedure.  
3.2.2.11 Mass spectrometry  
Electrospray-ionization mass spectrometry (ESI-MS) was carried out on purified samples of full length 
HtrA1 and ∆N-HtrA1. The analyses were performed at the IMP in Vienna, in the group of Karl 
Mechtler. 
3.2.2.12 Size Exclusion Chromatography (SEC)  
Size exclusion chromatography relies on the fact that molecules in solution are separated by size as 
they pass through a column packed with a chromatographic medium. The matrix consisting of 
microscopic beads with pores and internal channels function as a separation medium. Relatively 
small molecules can diffuse into the gel whereas large molecules will be prevented by their size from 
diffusing into the gel and are thus confined to the solution. Thus gel filtration displays a method that 
can be applied to further purify proteins and to determine the molecular mass of a molecule in order 
to characterize it. 
A calibration curve for molecular mass determination was set up as described. A gel filtration 
standard (BioRad) was used to determine the elution volumes (VE) of the following molecular mass 
standards: thyroglobulin (670 kDa), γ-globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and 
vitamin B12 (1.3 kDa). The total volume of the column (VT) was calculated according to its length and 
diameter.  Blue Dextran was used to determine the void volume of the column. The KAV value for 
every molecular mass standard was calculated:  KAV =  (VE – V0) / (VT – V0). 
The KAV
 
value for the molecular mass standards was then plotted against the logarithm of their 
molecular mass and the points were fit to a linear equation. For proteins with unknown molecular 
mass, the KAV value was determined and the corresponding molecular mass was calculated from the 
calibration curve. The KAV
 
value has the advantage that it is pressure independent. The analyses were 
carried out on a SMART-system (Pharmacia).  
The molecular mass of full length HtrA1, ∆N-HtrA1 and HtrA1-prot in solution was determined by 
analytical gel filtration chromatography on a Superdex-200 PC 3.2/30 and Superdex-200 10/300 
Materials and Methods          52 
 
column (Pharmacia). The columns were equilibrated with 50 mM ammonium sulphate, 10 mM 
HEPES/NaOH, pH 7.5 at 4°C or RT. Protein samples with a concentration of about 5mg/ml were 
applied to the column with 80μl/min for SD 200 PC 3.2 and 0.8 ml for SD 200 10/300. For SEC SD200 
26/60 during purification of HtrA1 refer to 3.2.2.7. 
To follow the complex formation of trimeric ∆N-HtrA1S328A with citrate synthase, 5 μl of 110 μM ∆N-
HtrA1S210A were incubated with 15 μl of 170 μM citrate synthase in 100 mM Tris-HCl (pH 7.5, 8, 8.5 or 
9), 150 mM NaCl for 15 min at 42°C prior to injection on a Superdex 200 (PC 3.2/30; GE Healthcare). 
Trimeric ∆N-HtrA1S328A and CS were used as a control. Runs were fractionated in parallel (100 μl 
fractions) and 10 μl samples were taken to check the content on SDS-PAGE. The experiment was 
done in addition for HtrA1-protS328A. 
To follow the complex formation with denatured lysozyme 5 μl of 110 μM ∆N-HtrA1S210A were 
incubated with 0.5 μl of 7 M lysozyme in 100 mM Tris-HCl (pH 8 or 9), 150 mM NaCl, 40 mM fresh 
DTT for 10 min at 42°C prior to injection on a Superdex 200 (PC 3.2/30; GE Healthcare). The final 
assay volume was 30 μl. Lysozyme was denatured and unfolded over night in 4 M urea, 40 mM DTT. 
Trimeric ∆N-HtrA1S328A and lysozyme were used as a control. Runs were fractionated in parallel (100 
μl fractions) and 10 μl samples were taken to check the content on SDS-PAGE.  
3.2.2.13 Dynamic Light Scattering (DLS)  
DLS was carried out using a DynaPro-801 (Protein-Solutions Inc.) molecular sizing instrument. A 50 μl 
sample of HtrA1S328A with a concentration of about 1mg/ml in 10 mM HEPES/NaOH, pH 7.5 was given 
into a 12 μl chamber quartz cuvette. The measurements were performed at 20°C. The data were 
analysed using the Dynamics 4.0 software (Protein-Solutions Inc.) as described by Moradian-Oldak et 
al. (1998) (Moradian-Oldak et al. 1998).  
3.2.2.14 Resorufin-labeled casein assay 
The proteolytic activity of HtrA1 and its derivatives was determined with resorufin-labeled casein 
(Roche, Germany). Fifteen microliters of 0.4% (w/v) resorufin-labelled casein was added to 100μl 
incubation buffer containing approximately 1 μM HtrA1. The mixture was incubated at 37°C for 
several hours. The reaction was stopped by precipitation of casein with 480 μl 10% (w/v) TCA. 
Samples were again incubated for 10 min. at 37°C and subsequently centrifuged (10 min, 10000 x g, 
RT). 400 μl of the supernatant was mixed with 600 μl 1 M Tris/HCl, pH 8.8 to determine the 
absorbance at 574 nm. A sample without HtrA1 was used as a blank.  
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Incubation buffer:   100 mM Tris/HCl pH 7.5 
100 mM NaCl  
3.2.2.15 ß-Casein degradation assay 
To follow the degradation of the model substrate ß-Casein 20 μM ∆N-HtrA1 or HtrA1-prot were 
incubated with 170 μM casein in 100 mM Tris-HCl pH 8.0 at 37°C. At certain time points the reaction 
was stopped by adding 2xSDS loading buffer to take aliquots. Subsequently, the aliquots were 
incubated for 5min at 95°C and analysed by SDS–PAGE. ∆N-HtrA1 and ß-Casein were detected by 
Coomassie stain. In parallel the degradation of ß-Casein was follwed in the presence of 100 μM 
peptide KKKDSRIWWV and incubating all three components in the same degradation buffer at 37°C.  
3.2.2.16 pNA-assay 
Serine proteinase activity of the enzyme was measured by the release of p-nitroanilidine (pNA) from 
substrates VFNTLPMMGKASPV-pNA and monitored by spectrophotometry at 405 nm. The activity of 
∆N-HtrA1 was measured in 100 μl reaction mixtures containing 10 μM ∆N-HtrA1, 100 mM Tris-HCl 
(pH 8 or 8.5) and 150 mM NaCl. The samples were preincubated for 10 min at 37°C, then the 
chromogenic substrate was added to a final concentration of 500 μM, and the increase in the 
absorbance at 405 nm and 37°C was measured continuously every minute with a fluorescence 96-
well plate reader (BioTek). The same assay conditions were performed at 42°C to measure the 
activity in the presence of citrate synthase, which was added prior to the 10 min incubation step with 
a final concentration of 20 μM. 
3.2.2.17 pNA-assay in the presence of peptides  
Cleavage assays concerning the influence of a certain peptide on the protease activity were 
performed by preparing a solution in incubation buffer (3.2.2.16) with a final concentration of 10 μM 
HtrA1 and 5 to 250 μM of the peptide. Again, reference as well as blank samples were prepared 
containing no peptides or no HtrA1, respectively. All the samples were preincubated for 10 min. at 
37°C, then 500 μM pNA substrate was added and the proteolytic activity was determined as 
described under 3.2.2.16. Every sample, the probe with the corresponding inhibitor as well as the 
reference was prepared three times. Average absorption values for the probe and the reference 
samples were calculated and the remaining activity of the inhibited probe was related to the 
reference. 
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The specific activity for HtrA1 was calculated using Lambert-Beer: ∆E = єmol x c x d with d = 0.3 cm 
(corresponding to the height of the liquid in the 96 well plate), єmol  = 8800 M
-1 x cm-1 as the 
extinction coefficient of the pNA and ∆E defined as the slope at the steepest part of the curve.  
3.2.2.18 pNA-assay in the presence of unfolded citrate synthase 
Peptidase activity of ∆N-HtrA1 was measured in 100 μl reaction mixtures containing 10 μM ∆N-HtrA1 
or HtrA1-prot and 20 μM citrate synthase in 100 mM Tris-HCl (pH 8 or 8.5) and 150 mM NaCl. The 
samples were preincubated for 10 min at 42°C then 500 μM pNA was added. The assay was done 
under the same conditions as described in 3.2.2.16 but at 42°C to measure the activity in the 
presence of citrate synthase. 
3.2.2.19 Inhibition of ∆N-HtrA1 with DPMFKLboroV peptide 
25 μM wild type protein was incubated with increasing amounts of the inhibitor peptide in 0.1 M Tris 
pH 8.5, 0.1 M NaCl. The assay volume was 100 μl. After 30 min incubation at 37°C, 160 μM ß casein 
was added and 5 μl samples were taken after 10 min for SDS-PAGE.  
3.2.2.20 Degradation of model substrates  
The degradation of substrate proteins by ∆N-HtrA1 and HtrA1-prot was analyzed by incubating a 
solution containing 80 μM HtrA1 in 100 mM Tris-HCl (pH 8.5), 100 mM NaCl with 7 mg/ml CS, or 5 
mg/ml MDH at 43°C. Samples were taken at certain time points and mixed with an equal volume of 
2x SDS loading dye to check the reaction on SDS-PAGE. After 3 hrs undigested proteins were 
removed by precipitation with six volumes of cold acetone. After incubation for 12 hrs at −20°C, 
samples were centrifuged for 30min at 4°C and 20,000 ×g. The pellet was discarded, and the acetone 
was removed from the supernatant in a SpeedVac. The pellet was resuspended in H2O. Peptides 
generated by ∆N-HtrA1 and HtrA1-prot were subjected to sequencing by mass spectrometry on a 
hybrid linear ion trap/Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FT Ultra, 
(ThermoFisher). For peptide identification, a database of all respective substrate proteins was 
generated, and the identified masses were searched against this database. The analysis was 
performed with the probability-based MASCOT software suite, version 2.2.0 (Matrix Science) without 
specifying any cleavage specificity. 
Materials and Methods          55 
 
3.2.2.21 Analysis of degradation products by mass spectrometry 
The analyses of the samples were carried out by the service department mass spectrometry at the 
IMP in the group of Karl Mechtler. Briefly, the degradation products were separated by reversed-
phase chromatography and subsequently applied to a Reflex III, MALDI-TOF mass spectrometer 
(Bruker Daltonics). Afterwards, individual peptides could be identified according to their molecular 
mass. The analyses of the raw mass spectrometry data were performed with Xcalibur mass 
spectrometry data system software (Thermo Electron Corporation).  
3.2.2.22 Isothermal Titration Calorimetry 
ITC is a thermodynamic technique that directly measures the heat released or absorbed during a 
biomolecular binding event.  Measurement of this heat allows accurate determination of binding 
constants (KB), reaction stoichiometry (n), enthalpy (∆H) and entropy (ΔS), thereby providing a 
complete thermodynamic profile of the molecular interaction in a single experiment.  
The thermodynamic values of the interaction between different constructs of HtrA1 and different 
peptides were determined by isothermal titration calorimetry (MCS-ITC; Microcal). All experiments 
were conducted in overflow mode at 30°C. 30 μM solution (1.4 ml) of ∆N-HtrA1 or HtrA1-prot were 
placed in the temperature-controlled sample cell and titrated with the peptide (300 μM), that was 
loaded in the 300 μL mixing syringe. For all experiments, 10 mM Hepes buffer, pH 7.5 supplemented 
with 50 mM (NH4)2SO4 was used as the buffer. Injections of 10 μL of peptide were dispensed into the 
sample cell using a 120 sec equilibration time between experiments and stirring at 300 rpm. Control 
experiments using the identical experimental setup were carried out in order to measure and correct 
the heat of dilution. Ultimately, the data were analyzed using ORIGIN software following the 
instructions of the manufacturer. 
 
3.2.3 Crystallographic methods 
3.2.3.1 Protein crystallization  
∆N-HtrA1 and ∆N-HtrA1S328A :  
For initial surveys of crystallization conditions, standard screening kits purchased from Hampton 
Research (USA) and Jena Bioscience were used, using a Cartesian Roboter or a Phenix Roboter. 
Therefore HtrA1S328A
 
at approximately 30 mg/ml was used with typically 0.1 μl or 0.2 μl of protein 
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solution mixed with 0.1 μl of reservoir solution set up as sitting-drop vapour-diffusion experiments 
using cryschem plates (Charles Supper Company, Massachusetts) with 500 μl of reservoir solution at 
4°C and 19°C, respectively. The initial condition consisting of 1.0 M LiSO4, 0.1 M sodium citrate pH 
5.8, 0.5 M (NH4)2SO4 was subsequently refined by a systematic variation of buffer, pH, drop ratio and 
by addition of certain additives to the drop mixture.  
∆N-HtrA1S328A (SeMet) and ∆N-HtrA1(SeMet):  
Crystals of HtrA1S328A(SeMet) were grown using sitting drops equilibrated against a reservoir of 1.0 M 
LiSO4, 0.1 M sodium citrate pH 5.6 to 6.3, 0.5 M (NH4)2SO4. Drops were set up with 2 μl HtrA1 
(SeMet) (30 mg/ml), and 1 μl or 2 μl reservoir solution.  
 
∆N-HtrA1 + Inhibitor:  
Crystals of wildtype ∆N-HtrA1 or ∆N-HtrA1(SeMet) were incubated with 2 mM (f.c.) of the inhibitor 
DPMPKLV-Boro for 30 min at ice, before setting up the co-crystallization trials. They were grown 
using sitting drops equilibrated against a reservoir of 1.0 M LiSO4, 0.1 M sodium citrate pH 5.6 to 6.3, 
0.5 M (NH4)2SO4. Drops were set up with 2 μl HtrA1-Inh
 
(30 mg/ml), and 1 μl reservoir solution.  
 
Fig. 3.2 DPMPKLV-Boro 
Depicted is the peptide inhibitor used for co-crystallization trials. The inhibitor molecule is composed of a peptide of seven amino acids and 
a boronic acid group fused at the C-terminus. The drawing was made with the program Chemograph. 
 
HtrA1-prot: 
Crystallization of HtrA1prot was done following the same procedure described for ∆N-HtrA1S328A first 
setting up initial screens and subsequent refinement. Big crystals appeared after one day in several 
conditions. Some of them have been refined. One finally condition for crystals taken for data 
collection experiments and structure solution contained 2.0 M ammonium sulfate and 0.1 M sodium 
acetate pH 4.6.  
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3.2.3.2 Improvement of diffraction properties - Seeding 
Crystals of ∆N-HtrA1 with bound inhibitor were used for seeding the following way in order to 
improve their diffraction properties. After crystallization at room temperature, a single crystal was 
fished and crushed in 50 μl reservoir solution. The seeding solutions were prepared using the Seed 
Bead Kit from Hampton Research. Dilutions were prepared from 10-1 to 10-6. Drops were set up using 
the Oryx Robots with 1 μl HtrA1 in complex with the inhibitor, 1 μl reservoir solution and 0.3 μl 
seeding solution. Crystal grew for four weeks and were then flash frozen by plunging into liquid 
nitrogen using 1.8 M LiSO4 as a cryoprotectant and maintained at ~100 K in a nitrogen gas stream 
during data collection.  
3.2.3.3 Data collection and data processing  
Single crystals were mounted in Hampton Research Cryo loops of appropriate size, flash frozen to 
100K in a cold nitrogen-gas stream and subjected to X-ray diffraction. Before the crystals were 
transferred to cryobuffer for several seconds prior to flash-freezing in order to avoid ice rings and 
crystal damage due to cooling. Data were collected at beamline ID14-4 at the ESRF (Grenoble, 
France) or at beamline X06SA at the SLS (Zurich, Swiss). 
For MAD experiments, prior to data collection an X-ray fluorescence spectrum of the respective 
crystal was recorded in order to determine the peak, inflection and remote wavelength 
corresponding to the anomalous scatterer present in the crystal. After recording and processing a 
test oscillation image, the angle range which is necessary to achieve an optimal completeness was 
determined by using the program STRATEGY (Leslie, 1992). The most precise anomalous differences 
are obtained by collecting the so-called Friedel mates at inverse beam geometry. For this purpose, 
for every wavelength a second data set was collected after rotating the crystal by 180° corresponding 
to the first starting value.  
All diffraction data were processed and scaled using the programs DENZO, SCALEPACK (Otwinowski 
and Minor, 1997) and HKL2000 or XDS. The indexed intensities were converted and reduced to 
structure factors using the program TRUNCATE from the CCP4 program suite (Bailey, 1994).  
 
Cryobuffer ∆N-HtrA1:            1.8 M LiSO4, 0.1 M Na-citrate pH 6.0, 0.6 M (NH4)2SO4 
 
Cryobuffer for HtrA1-prot:    0.1 M Na-acetate pH 4.6 and 2 M (NH4)2PO4, 20% Glycerol 
Materials and Methods          58 
 
3.2.3.4 Structure solution  
∆N-HtrA1S328A: 
The structure was determined by molecular replacement using the program Phaser of the CCP4 
package (CCP4, 2002) and the protease domain (residues 140 - 340) of human HtrA2 (Protein Data 
Bank ID 1LCY) as a search model. Electron density maps based on the coefficients 2Fo-Fc and 3Fo-2Fc 
were calculated from the phases of the initial model. The resulting maps were used to build atomic 
models in O (Jones et al. 1991). Refinement and model rebuilding proceeded smoothly via rigid body, 
positional, and later B factor optimization in CNS (Brunger et al. 1998). The entire structure was 
checked using simulated annealing composite omit maps. Some protein segments including residues 
158 – 160, 301 – 314 (Loop L3) and 371 - 480 (PDZ domain) were hardly visible or invisible in these 
maps and were therefore omitted from the model. The refined HtrA1S328A structure was used to solve 
the structure of the inhibitor complex of HtrA1.  
 
∆N-HtrA1 + Inhibitor 
A complete dataset for the HtrA1 inhibitor complex was measured at the Swiss Light Source (SLS, 
Beam line X06SA) at λ = 0.9724 Å using a Pilatus detector (Dectris). The crystals also belonged to 
spacegroup H 3 with slightly different cell constants of a = 105.965, b = 105.965, c = 118.336. During 
refinement of the HtrA1 inhibitor complex, clear electron density developed for one inhibitor 
molecule within the active site of the protein. In contrast to ligand-free HtrA1, the entire protease 
domain was well defined. Especially the proteolytic site that underwent pronounced conformational 
remodeling was carefully inspected. In these maps, residues 158 - 159 and 371 - 480 had to be 
omitted from the model due to high flexibility. 
As the crystals of HtrA1-Inh were nearly isomorphous to the HtrA1S328A crystals, the coordinates, 
constructing the asymmetric unit of the HtrA1S328A structure were used to calculate an initial rigid-
body refinement, using data from 20 – 3.2 Å. After this procedure, both Rwork and Rfree dropped well 
below 40%. 
 
HtrA1-prot 
The structure was determined by molecular replacement using the program Phaser of the CCP4 
package (CCP4, 2002) and the protease domain (residues 140 - 340) of human HtrA2 (Protein Data 
Bank ID 1LCY) as a search model. Electron density maps based on the coefficients 2Fo-Fc and 3Fo-2Fc 
were calculated from the phases of the initial model. The resulting maps were used to build atomic 
models in O (Jones et al. 1991). Refinement and model rebuilding proceeded smoothly via rigid body, 
Materials and Methods          59 
 
positional, and later B factor optimization in CNS (Brunger et al. 1998). The entire structure was 
checked using simulated annealing composite omit maps. Crystals of the protease domain belonged 
to the tetragonal spacegroup P43212 with cell constants a = 153.671, b = 153.671, c = 89.835 
containing three molecules per asymmetric unit. Protein segments including residues 158 – 160, 301 
– 314 and 365 - 373 were hardly visible or invisible and were therefore omitted from the model.  
3.2.3.5 Model building and refinement 
The program O (Jones et al. 1991) was used for model building. For HtrA1S328A and HtrA1-Inhibitor 
energy-restrained crystallographic refinement was carried out with maximum likelihood algorithms 
implemented in CNS (Brunger et al. 1998), using the protein parameters of Engh and Huber (1991) 
(Engh and Huber, 1991). Bulk solvent, overall anisotropic B-factor corrections and non-
crystallographic (NCS) restraints were introduced depending on the behaviour of the free R index. 
Refinement proceeded in several cycles, which were interrupted for manual rebuilding with the 
program O. The stereochemistry of the model was validated with PROCHECK (Laskowski et al. 1993).  
3.2.3.6 Graphical representations and sequence alignments  
Graphical presentations as well as surface and electrostatics calculations were prepared with the 
program PyMOL (DeLano 2004). Initial sequence alignments were made with ClustalW 
(http://www.ch.embnet.org/software/ClustalW.html) and presentations of sequence alignments 
were made with ESpript (Gouet et al. 1999).Secondary structure predictions were made with the 
program HHPred (http://toolkit.tuebingen.mpg.de/hhpred).  
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4 Results 
4.1 Purification of HtrA1 
4.1.1 Purification of full length HtrA1 
HtrA1 consists of three different domains, an N-terminal domain with unknown function, a serine-
protease domain and one C-terminal PDZ domain (Clausen et al. 2002). The N-terminal region of 
HtrA1 contains 18 cysteines which potentially form several disulfide bonds and may be necessary for 
proper folding of the protein. Expression and purification of the deletion construct containing the 
protease- and PDZ domain was established in E. coli as described in 4.1.2. So far, it has been possible 
to express the full length HtrA1 in an eukaryotic expression system (ProteaImmun, Berlin). This 
expression system showed limitations as the amount of purified protein was not sufficient for crystal 
trials. Eucaryotic expression systems are nevertheless beneficial if posttranslational modifications like 
disulfide bond formations are needed as the cytoplasm of E. coli is reducing and does not allow S-S 
bond formation. This may be the reason why so far any attempt to express HtrA1 in an E. coli 
expression system has failed. 
Several strategies were performed to express HtrA1 in E. coli. Besides cloning of different tags which 
could enhance the solubility of the protein, different bacterial strains and the secretion to the 
periplasm of E. coli were tested for expression. Finally the expression of the full length HtrA1 in 
fusion with a Thioredoxin-tag (TrxA-tag) in E. coli Origami B cells has been successful (see 3.2.2.7 for 
cloning strategy) and is described below.  
The full length protein as well as the N-terminal domain (NT-HtrA1) of HtrA1 both without the signal 
sequence (residues 1-21) were expressed and purified. The purification included NiNTA affinity 
chromatography and size exclusion chromatography (SEC).  After loading the cell lysate to the NiNTA 
column washing with a stepwise increasing imidazole concentration removed unspecific bound 
proteins. Loading the fractions on a SDS-PAGE showed a 72 kDa protein in the elution fraction which 
Results           61 
 
corresponds to the expected size of HtrA1 in combination with the TrxA-tag. Figure 4.1 gives an 
example of the NiNTA chromatography profile.  
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Fig. 4.1 NiNTA purification of HtrA1S328A      
A) NiNTA chromatography for HtrA1S328A. Increasing imidazole concentrations are indicated. Fractions are loaded on a SDS-PAGE shown in 
B) following Coomassie blue staining. B) Lane 1 whole cells, 2 load, 3 flow through, 4 wash I, 5 elution with 150 mM imidazole. The arrow 
indicates HtrA1 in fusion with a TrxA-tag with the expected size of 72 kDa. 
 
After NiNTA the 150 mM imidazole elution fraction was buffer exchanged into buffer B (without 
imidazole) and concentrated to 5 ml. The TrxA-tag was cleaved with PreScission protease (GE 
Healthcare) over night at 4°C. Samples were taken at different time points to monitor the cleavage. 
Subsequently, SEC was performed on a Superdex 200 column to separate the TrxA-tag and the 
PreScission protease from HtrA1. The SEC profile is shown below. 
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Fig. 4.2 SEC profile of full length HtrA1S328A            
SEC was performed after cleaving the TrxA-tag with PreScission protease. The protein was concentrated and injected to a SD 200 26/60 
column via a 2 ml loop. 2 ml fractions were collected and analysed by SDS-PAGE. Four peaks can be distinguished. Peak 1 elutes in the void 
volume, peak 2 corresponds to trimeric HtrA1, peak 3 contains PreScission protease and peak 4 the cleaved TrxA-tag. 
 
Four peaks were detected on SEC and loaded on a SDS-PAGE. Figure 4.3 shows that HtrA1 was 
cleaved yielding a 51 kDa protein corresponding to the expected size. PreScission protease as well as 
the tag elute as single peaks with a molecular weight of 48 kDa and 17 kDa, respectively.  
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Fig. 4.3 SDS PAGE of SEC fractions  
Fractions of SEC were loaded on a SDS-PAGE following Coomassie blue staining: 1 (control) PreScission protease (48 kDa) from GE 
Healthcare, 2-6 peak 1 (void), 7-9 peak 3 (PreScission), 10-12 peak 2 (corresponding to HtrA1, 51 kDa), 13 peak 4 (TrxA-tag, 17 kDa). 
 
 
SEC showed that HtrA1S328A forms a trimer in solution and is about 95% pure after the two step 
purification. The TrxA-tag is cleaved efficiently after 2 hrs incubation at 4°C (not shown). The protein 
was taken for initial crystallization trials but so far no crystals could be obtained. 
The wild type protein was purified according to the same protocol described for the inactive mutant 
but showed degradation during NiNTA chromatography (Fig. 4.4). The three degradation bands were 
identified by mass spectrometry to be HtrA1. Therefore, the wild type protein seems to undergo auto 
degradation. Cleavage by endogenous proteases could be excluded because the same purification 
protocol was applied for the inactive and the active mutant and degradation would occur also for the 
inactive mutant. All cleavage sites lie within the region between the N-terminal domain and the 
protease domain, yielding constructs of around 38 to 45 kDa consisting of the protease and the PDZ 
domain as shown in figure 4.4. 
In order to map the cleavage sites all three bands of the wt protein (Fig. 4.4) were cut out from the 
gel and digested with trypsin, chymotrypsin and subtilisin and subjected to mass spectrometry 
analysis. One cleavage site could be identified with this method and was confirmed by N-terminal 
sequencing as described below.  
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Fig. 4.4 NiNTA fractions of wt HtrA1 
Samples were taken after different steps during NiNTA chromatography and subjected to SDS-PAGE following Coomassie blue staining. 
Lane 1 shows uninduced cells, lane 2 load, lane 3 wash I, lane 4 wash II, lane 5 elution with 150 mM imidazole. Arrows indicate self 
cleavage products of wild type HtrA1.  
4.1.1.1 Folding status of HtrA1 
To confirm the folding of full length HtrA1 and the formation of disulfide bonds, reduced and non 
reduced protein samples were analysed by SDS-PAGE. Figure 4.5 shows that the reduced form of 
HtrA1 displays a different mobility on a SDS-PAGE compared to the non reduced protein. As disulfide 
bond formation takes place the protein is likely to be folded. To further approve the the folded state 
of HtrA1 different experiments could be considered and are discussed under 5.1.  
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Fig. 4.5 Reduced and not reduced samples of HtrA1S328A on SDS-PAGE   
Samples were mixed 1:1 with 2xLoading buffer either with or without DTT, boiled at 95°C for 5 min and subjected to SDS-PAGE following 
Coomassie blue staining. Lane 1 and 2 show DTT-reduced HtrA1. Lane 3 and 4 show not reduced HtrA1 running faster on SDS-PAGE. 
 
4.1.2 Purification of ∆N-HtrA1 and ∆N-HtrA1S328A 
4.1.2.1 Design of deletion constructs 
In order to crystallize HtrA1 and assess its biochemical properties, deletion constructs of HtrA1 were 
designed taking into consideration that full length HtrA1 did not crystallize and additionally 
undergoes auto degradation (see 4.1.1). One strategy for successful crystallization is to clone only 
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stable parts of the protein and to shorten the constructs at the N- or C-termini. Furtherrmore auto 
degradation leads to a heterogeneous protein composition, usually making protein crystallization 
impossible (Ferré-d'Amaré and Burley, 1994).  
Originally the gene was expressed and purified from pSG7 or pSG13 (Grau et al. 2005) which did not 
express the N-terminal domain of HtrA1 (residues 1 to 139). The expression from these vectors which 
are derivatives of pQE60 (Qiagen) yielded only small amounts of HtrA1 but high amounts of the Lac 
repressor protein (LacI). LacI was found to unspecifically bind to Ni-columns and was purified instead 
of HtrA1. This was due to the fact that the monomeric size of LacI with 38 kDa is the same as for the 
expressed HtrA1 construct and the formation of the tetramer could not be distinguished from a 
trimer of HtrA1 on SEC. Different purification procedures were tried including a Hydroxylapathite 
column, a MonoQ, DEAD column, Heparin columns and others. Using the pET vecter expression 
system (pET21d) instead yielded a much higher overexpression of HtrA1 and thus facilitated a proper 
enrichment of the protein. PCR amplification and cloning of HtrA1 into pET21d expressed a C-
terminal His6-tagged protein in E. coli BL21 (DE3) cells (3.2.2.8). Nevertheless, this protein still 
showed auto degradation and the design of other deletion constructs was necessary. 
The auto cleavage site could be verified by N-terminal sequencing (4.1.2.2) and gave rise for the first 
construct. The design was furthermore based on a secondary structure prediction with HHPred for 
HtrA1 as shown in Fig. 4.6 and alignments with DegP and DegS the bacterial homologs. Finally three 
constructs were cloned and expressed as shown in the Fig. 4.6. 
1 2 3
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Fig. 4.6 Designing deletion constructs for expression in E. coli 
Secondary structure prediction for HtrA1 was made with HHPred and is indicated above the amino acid sequence for HtrA1. Arrows 
indicate starting points of the constructs taken for cloning and expression in E. coli. Construct 1 marks the self cleavage site identified by N-
terminal sequencing, construct 2 is based on the predicted secondary structure for HtrA1, construct 3 is based on a sequence alignment 
and the secondary structure of DegS. 
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All constructs were cloned and expressed but only construct 2, later referred to as ∆N-HtrA1, could 
be successfully purified and concentrated for crystallization trials and is discussed in the following 
sections of this work. Construct 3 was unstable and precipitated after NiNTA purification. From the 
structure solved during this work it became obvious that Tyr169, Phe171 and in addition the N-
terminal half of the α-helix including Leu165 and Arg166 are important to mediate trimer formation 
of HtrA1. It has been therefore concluded that the assembly of the trimer was disrupted and HtrA1 
was not stable as a monomer in solution.  
4.1.2.2 N - terminal sequencing 
Wildtype HtrA1 undergoes self cleavage which could interfere with crystal growth. Therefore it was 
necessary to map the cleavage sites to express a stable construct. After SDS-PAGE, ∆N-HtrA1 was 
blotted to a PVDF membrane, the degradation band cut out from the membrane and subsequently 
analyzed by N-terminal sequencing. The analysis has been carried out at Alphalyse in Denmark. The 
sequence of the first N-terminal residues is L-Q-A/R-A-A-Q, which could correspond to the N-terminal 
residues L-Q-R-G-A of HtrA1. A protein starting at these residues would correspond to a 36 kDa 
fragment and it was assumed that the cleavage occurs between Val149 and Leu150. This is in good 
agreement with results showing that HtrA1 has a preference for small hydrophobic residues such as 
valine and leucine at the P1 site (Fig. 4.22). 
4.1.2.3 Purification 
The wild type ∆N-HtrA1 and the inactive mutant ∆N-HtrA1S328A were purified the same way. The 
overexpression and purification of the proteolytically inactive variant of HtrA1 was indistinguishable 
from that of the wild type. 
The purification procedure involved Ni-NTA affinity and size exclusion chromatography (SEC) and a 
more than 95% pure protein as estimated from SDS-PAGE was obtained after this two-step 
purification protocol (Fig. 4.8 B). In the first step, the His-tagged ∆N-HtrA1 was bound to a NiNTA 
column (Amersham) applying the whole cell lysate. The column was washed with a buffer containing 
30 mM imidazole and HtrA1 was finally eluted with 150 mM imidazole (Fig. 4.7). Fractions containing 
the 150 mM elution step were collected, concentrated and further purified by SEC or taken for 
methylation. The protein yield at this stage was approx. 8 mg from 1 l culture. 
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Fig. 4.7 Ni-NTA elution profile of His6-tagged wt ∆N-HtrA1 
The corresponding imidazole concentrations are indicated in the elution profile. The collected fractions were loaded on a 12% SDS-PAGE 
gel (see figure 4.8). The elution fraction depicted in blue was collected for the next purification step. 
 
Size exclusion chromatography was performed on a Superdex 200 prep grade gel filtration column. 
The resulting gel filtration profile showed a small aggregation peak eluting in the void volume of the 
column (P1) and two peaks corresponding to HtrA1 (Fig 4.8 A). The molecular mass of the third peak 
was according to the calibration of the column 120 kDa, which corresponds to a trimer of ∆N-HtrA1. 
SDS-PAGE analysis of this peak fractions indicated that the protein preparation was > 95% pure (Fig. 
4.8 B) for both the wild type and the SA mutant. The collected P3 fractions yielded 30 mg of highly 
pure protein which was subsequently used for further experiments. Strikingly, the wild type protein 
with the N-terminal deletion did not show self cleavage any more and was taken for crystallization. 
The protein was concentrated for biochemical assays or further treated by methylation (4.1.2.4).  
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Fig. 4.8 SEC elution profile and SDS-PAGE of ∆N-HtrA1 purification  
A) 150 mM elution peak from Ni-NTA column was concentrated and applied over a 2ml loop to a Superdex 200 26/60 column (GE 
Healthcare) equilibrated with 10 mM HEPES pH 7.5, 50 mM (NH4)2SO4. Indicated fractions were analysed by SDS-PAGE (right). P3 fractions 
were pooled separately, concentrated and stored at -80°C. B) SDS-PAGE shows in lanes 1 and 2 ∆N-HtrA1S328A after NiNTA and SEC, 
respectively. Lanes 3 to 6 show wild type ∆N-HtrA1: in 3 P1, in 4 P2, in 5 P3 after SEC and in 6 after NiNTA purification. 
A) B) 
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4.1.2.4 Methylation 
For successful crystallization methylation of lysine residues of ∆N-HtrA1 and ∆N-HtrA1S328A was 
necessary. Methylation of lysines leads to decreased solubility of the protein and was first described 
by Walter et al. 2006. The trimeric peak fraction of ∆N-HtrA1 was taken directly after SEC and 
incubated with formaldehyde and ABC solution as described in 3.2.2.9. After stopping the reaction 
the protein was concentrated to 2 ml and injected to a Superdex 200 column. The protein eluted as 
one single peak from the column. The elution volume and the mass of the protein judged from SDS-
PAGE were slightly higher than for the unmethylated protein indicating that methylation was 
successful. As shown in 4.4 the methylated protein retained proteolytic activity. 
4.1.3 Purification of the protease domain of HtrA1 (HtrA1-prot) 
Purification of the protease domain of HtrA1 was performed mainly as described for ∆N-HtrA1. The 
construct was designed based on the ∆N-HtrA1 deletion construct. The two-step purification yielded 
> 95% pure protein as judged by SDS-PAGE. SEC on a SD 200 26/60 column showed an elution peak in 
the void volume of the column and one peak at 202 ml corresponding to a dimer or a trimer of 
HtrA1-prot. To verify the oligomeric state of the protease domain analytical SEC on a Superdex 75 
was performed. The result is shown in figure 4.10 and confirms that HtrA1-prot forms a trimer in 
solution.  
4.1.4 Purification of selenomethionine substituted ∆N-HtrA1 
The proteins ∆N-HtrAS328A(SeMet) and ∆N-HtrA1(SeMet) were expressed in methionine auxotroph 
B834 cells. The expression in minimal-medium and B834 cells was slower but yielded comparable 
amounts with 10 mg/l as for the expression in LB media. ∆N-HtrA1S328A(SeMet) and ∆N-HtrA1(SeMet) 
were purified as decribed in 4.1.2.3 for the not selenomethionine substituted protein. SEC showed a 
distinct peak for a higher oligomeric species and was analysed by SDS-page. The P2 peak fraction 
contained highly pure HtrA1 and an additional band of approx. 35 kDa. Mass spectrometry analysis 
identified this band as the outer membrane protein A (OmpA) from E. coli (4.1.4.1). Fractions 
containing only the trimer of HtrA1 (P3) were pooled and used for methylation and crystallization.  
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Fig. 4.9 SEC profile and SDS-PAGE for selenomethionine substituted ∆N-HtrA1 
A) SEC profile showing three peaks which were loaded to an SDS-Page shown in B. B) Peak1 (P1), peak2 (P2) and peak3 (P3) are loaded to 
an SDS-PAGE. The elution volume of P3 corresponds to a trimer of HtrA1.Peak2 shows beside HtrA1 one additional band around 35 kDa. 
The band was cut and identified by mass spectrometry as OmpA from E. coli. 
 
4.1.4.1 Mass Spectrometry 
To confirm the identity of the purified proteins mass spectrometry was performed. The SA mutant of 
the full length HtrA1 and ∆N-HtrA1 were both identified by mass spectrometry in the group of Karl 
Mechtler in the IMP in Vienna. The protein bands were cut from SDS-PAGE and digested with trypsin. 
The obtained peptides were than searched against the E. coli and the human proteom.  
SEC showed for wt HtrA1 and HtrA1S328A
 
protein three different peaks and analysis of the second peak 
which could correspond to a higher oligomer of HtrA1 SDS-PAGE analysis clearly revealed two 
distinct bands with an estimated molecular weight of 38 kDa and approx. 30 to 35 kDa (Fig. 4.9). The 
upper band corresponds to the HtrA1 protein whereas the lower band resulted in the identification 
of the E. coli porin OmpA which runs with a molecular mass of 35 kDa if unfolded and 30 kDa if 
folded.  That HtrA1 co-purifies with bacterial OmpA is interesting as for the bacterial homolog DegP it 
was shown to bind folded OMP´s forming 12meric or 24meric particles (Krojer et al. 2008). This result 
indicated that HtrA1 is able to form higher oligomeric complexes (see below). 
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4.2 Oligomeric state of HtrA1 in solution 
4.2.1 Oligomeric state of HtrA1-prot 
The oligomeric state of HtrA1-prot could not be distinguished between a dimer and a trimer after 
SEC on a SD 200 26/60. Thus analytical SEC on a SD 75 10/300 has been performed. From this column 
the protein elutes at 10.1 ml as a single peak. The calculated protein size for this volume is 67 kDa 
which is similar to the expected size of a trimer with 75 kDa. Additional the observed trimeric state of 
full length HtrA1 and ∆N-HtrA1 after preparative SEC (Fig. 4.2 and Fig. 4.8) could be confirmed for 
both proteins in analytical SEC (data not shown).   
 
Fig. 4.10 Chromatogram HtrA1-protS328A 
HtrA1-prot was subjected to a SD 75 10/300 column. It eluted as a single peak with an elution volume of 10.1 ml which corresponds to a 
trimer of the protease domain. 
 
4.2.1.1 Oligomerization in the presence of unfolded substrates 
As the bacterial homolog DegP is activated by forming higher oligomeric complexes with substrates, 
namely 12- or 24mers, this function was also investigated for HtrA1. HtrA1 cleaves unfolded 
substrates like chemically denatured lysozyme and heat denatured citrate synthase (CS). These two 
substrates were incubated with ∆N-HtrA1S328A and subjected to size exclusion chromatography. In 
figure 4.11 A the chromatogram is shown for the incubation with citrate synthase.  Three peaks can 
be clearly distinguished. Both proteins were additionally injected alone to the column to determine 
their elution volume which facilitates the correct assignment of the peaks in the elution profile of 
∆N-HtrA1 incubated with CS. Peak 2 contains trimeric ∆N-HtrA1 (elution volume 1.33 ml) and peak 3 
citrate synthase (elution volume 1.54 ml). Peak 1 (elution volume 1.1 ml) contains both HtrA1 and CS 
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suggesting that HtrA1 forms a higher oligomeric species when incubated with unfolded substrates. 
To verify this result peak 1 was collected and reinjected to the column showing the same elution 
volume (data not shown) indicating the formation of a stable complex. It could be furthermore 
shown that the oligomer formation is pH dependent as the switch was more prominent at pH 9 than 
at pH 7.5 or 8.5. 
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Fig. 4.11 SEC for ∆N-HtrA1S328A incubated with unfolded citrate synthase at pH 9 
A) ∆N-HtrA1S328A was mixed with CS, incubated for 10 min at 42°C and injected to a SD 200 PC 3.2 Three peaks are labelled and fractions 
indicated were loaded on a SDS-PAGE. Fraction 2 and 3 show co-elution of HtrA1 and CS, fractions 4 and 5 show HtrA1 (trimer), fractions 6 
and 7 show CS. B) Overlay of normalized elution profiles of ∆N-HtrA1 after incubation at 42°C (green dotted line) and CS  (blue dotted line) 
if injected separately to SEC. Both elute as a single peak. C) PH dependent oligomer formation is shown. Black curve shows oligomer 
formation at pH 9.0, blue curve at pH 8.5 and grey curve at pH 8. 
 
In a control reaction HtrA1 was incubated alone at 42°C or HtrA1/CS at 37°C and no complex 
formation could be determined by SEC which is consistent as CS starts to unfold at 42°C but is folded 
at 37°C. These data indicate that the HtrA1 trimer is transformed into a larger multimer in the 
presence of unfolded substrate. It can only be speculated if this multimer corresponds to a defined 
particle of HtrA1, e.g. a 12mer, or if HtrA1 is clustering around unfolded substrates.  
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The complex formation was additionally investigated for unfolded, denatured lysoyzme (Fig. 4.12) 
also showing a shift on SEC. No single peak for HtrA1 remained, as seen for the incubation with 
unfolded CS (Fig. 4.11 A), indicating that ∆N-HrA1 completely shifted into the oligomeric species.  The 
complex fraction showed co-elution of both proteins as judged by SDS-PAGE (not shown). The elution 
fraction was taken for negative stain electron microscopy (Fig. 4.12). As judged from the picture the 
fraction reveals homogenous particles with a diameter of approx. 120 Å.  
 
Fig. 4.12 SEC of ∆N-HtrA1 incubated with Lysozyme and negative stain of complex fraction 
∆N-HtrA1S328A was mixed with lysozyme, incubated for 10 min at 37°C and injected to a SD 200 PC 3.2. The peak containing HtrA1 and 
lysozyme was taken for negative stain. The green dotted line indicates the normalized elution volume of HtrA1 as a trimer if injected to the 
column separately without unfolded substrate. Electron microscopy revealed a homogeneous fraction showing defined particles with a 
diameter of approx. 120 Å. The scale bar refers to 100 nm. 
 
Strikingly CS incubated at 42°C for 10 min and denatured lysozyme incubated at 37°C for 10 min 
precipitated as visible to the naked eye which could be prevented by the addition of HtrA1. Thus 
HtrA1 seems to prevent formation of aggregates and has the ability to keep unfolded proteins.  
The formation of complexes with OmpA and ß-casein was also possible, nevertheless these 
complexes were not as stable as with CS or lysozyme as they could not be reinjected to the column 
without falling apart (data not shown). 
Figure 4.13 shows that similarly to ∆N-HtrA1 HtrA1-prot does form a higher oligomer species. HtrA1-
prot elutes with 1.51 ml, CS with 1.54 ml. Therefore the two peaks overlap and it can not be 
concluded that all of the protease shifts. As checked by SDS-Page both peaks contain both proteins 
indicating that not all of the protease shifts into the oligomeric species. The occurrence of the higher 
order oligomer suggests that the PDZ domains are not required to trigger HtrA1 assembly in 
multimers and should not be part of the newly formed multimeric interfaces. 
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Fig. 4.13 SEC of HtrA1-prot incubated with unfolded citrate synthase at pH 9 
HtrA1-prot was mixed with CS, incubated for 10 min at 42°C and injected to a SD 200 PC 3.2. Two peaks occur which contain both HtrA1-
prot and CS as labelled above and checked by SDS-Page. 
 
The complex fraction was re-applied to the column showing again the complex fraction but in 
addition a peak at around 1.5 ml corresponding either to HtrA-prot, CS or both (data not shown). This 
indicates that the complex is not as stable as for ∆N-HtrA1 as it tends to fall apart and points to a 
stabilizing effect of the PDZ domain or a function in binding substrates. 
4.2.2   Dynamic light scattering 
Dynamic light scattering was employed as a second method to determine the apparent molecular 
weight of ∆N-HtrA1S328A
 
alone and in complex with citrate synthase in solution and additionally for 
HtrA1-prot. As the underlying physical principle is different to size-exclusion chromatography, the 
results should support the reliability of the previously determined molecular weights and should give 
an indication how likely the proteins will crystallize. Measurements for HtrA1 and complexed HtrA1 
were carried out at 19°C and further processed with the program Dynamics 4.0 (Protein-Solutions 
Inc.) with the following results: 
 
Tab. 4.1 Dynamic light scattering 
Parameter  HtrA1S328A HtrA1S328A + CS HtrA1-prot 
 
RH(nm)  4.81 3.30 9.62 3.80 
MW
 
(kDa)  133 55 673 77 
CP/RH 
(%)  13.0 8.7 14.8 13.7 
Baseline  1.002 1.001 1.001 1.001 
SOS  14.87 15.62 15.62 17.81 
Tab. 4.1 Dynamic light scattering RH: hydrodynamic radius, MW: molecular weight, CP/RH: polydispersity index, CP: standard deviation of 
RH, SOS: sum of squared  
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The interpretation and the use of the statistical parameters as calculated by Dynamics 4.0 are given 
below. The values have been adapted from the DynaPro-801 Operator Manual: 
 
Tab. 4.2 Interpretation and use of the statistical parameters as calculated by Dynamics 4.0 (Protein Sol. Inc.) 
Parameter  Interpretation  
Baseline  
0.977-1.002  Monomodal distribution  
1.003-1.005  Bimodal distribution  
>1.005  Bimodel/multimodal distribution  
Sum of Squared (SOS)  
1.000-5.000  Low noise, negligible error  
5.000-20.000  
Background error owing to noise, low protein concentration or a 
small amount of polydispersity  
>20.000  
High noise/error owing to high polydispersity in size distribution 
(aggregation), irregular solvent  
Polydispersity  
Note: this parameter should be used for monomodal distribution 
only  
CP/RH  <15%  Monodisperse solution, likely to crystallize  
CP/RH 
 <30%  A moderate amount of polydispersity, possible to crystallize  
CP/RH 
 >30%  A significant amount of polydispersity, less likely to crystallize  
Tab. 4.2 RH: hydrodynamic radius, MW: molecular weight, CP/RH: polydispersity index, CP: standard deviation of RH, SOS: sum of squared  
 
HtrA1-prot and ∆N-HtrA1 alone and in complex with CS show a monomodal distribution and a 
monodisperse solution. They can therefore be considered to crystallize which was tried for ∆N-HtrA1 
and HtrA1-prot successfully. Furthermore the calculated molecular weight is close to the expected 
mass of 120 kDa for a ∆N-HtrA1 trimer and 75 kDa for a HtrA1-prot trimer. Analysis of samples 
containing ∆N-HtrA1 and CS showed two peaks in the corresponding graph (not shown). The values 
in the table show that the smaller peak could correspond to not complexed CS (free substrate) as the 
calculated MW is 55 kDa and therefore similar to a monomer of CS (45 kDa). The 673 kDa peak could 
correspond to a higher oligomeric particle of HtrA1 formed upon substrate binding. The mass for a 
HtrA1 12-mer is approx. 440 kDa suggesting that roughly 4 CS monomers would be bound to HtrA1.  
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4.3 Isothermal Titration Calorimetry (ITC) 
PDZ domains are protein-protein interaction modules which bind the C-termini of target proteins. So 
far only little is known about peptides binding to the PDZ domain of HtrA1 and about the 
consequences for proteolytic activity. For the bacterial homologs like DegS and DegP it is known that 
binding of peptides to the PDZ domains can alter proteolytic activity or is necessary to activate the 
protease. For HtrA1 it was shown using phage-displayed peptide libraries that hydrophobic peptides 
with a broad range bind to the PDZ domain of HtrA1 (Runyon et al. 2007) and it was proposed that 
binding of peptides to the PDZ may alter proteolytic activity (Runyon et al. 2007).  In order to identiy 
peptides binding to the PDZ domain of HtrA1 and to determine their binding affinity, ITC 
measurements with several candidate peptides were done. Candidates were chosen with regards to 
published data by Runyon et al. and known preferences from the bacterial homologs DegS and DegP 
(Hasselblatt et al. 2007, Krojer et al. 2008). The following peptides were tested and binding affinities 
determined if possible: 
 
Tab. 4.3 Peptides tested in ITC and their calculated binding constants 
Peptide Kd (μM) 
TPVFNTLPMMGKASPV  (1637) Nd 
SPMFKGVLDMMYGGMRGYQV  (2049, DegP ligand)  nd * 
FANQHLCGSHLVEA  (2327, HtrA1-pNA peptide) nd * 
HLVEALDMMYGGMRGYQF  (2356, DegP ligand) nd * 
KKKKCQYYFV  (2358)  181 
KKKKDSRIWWV  (2359) 21 
QVVATATFRF  (2371, DegS ligand) nd * 
DNRDGNVYQV  (2377, DegS ligand) nd 
DNRDGNVFRF  (2379, DegS ligand) nd 
DNRDGNVWWF (2380, DegS ligand) nd 
KGIKDVVTQPQA (2677) nd 
Tab. 4.3 ITC buffer contained 10 mM Hepes, pH 7.5 and 50 mM ammonium sulphate.                                                                                              
nd = not detectable, * indicates that 3% DMSO was necessary to dissolve the peptide 
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All peptides were used in a concentration of 300 μM and ∆N-HtrA1 with 30 μM. Four peptides (2049, 
2356, 2327 and 2371) had to be dissolved in 3% DMSO to be solubilized (Tab. 4.3). To measure the 
affinity to HtrA1 the protein solution had to contain 3% DMSO. It can not be excluded that DMSO 
interfered with peptide binding and therefore no affinity could be measured. 
Peptide 2359 was soluble in buffer without DMSO and was determined to bind with a KD of 13.4 μM 
to ∆N-HtrA1. Subsequently the binding was furthermore tested for the methylated protein which 
showed comparable binding of the peptide with a KD of 21 μM and demonstrated that methylation 
does not impair binding of peptides to HtrA1.  
To clarify if the binding occurs to the PDZ domain and/or the protease domain of HtrA1, ITC was 
performed with HtrA1-prot. No binding could be observed in a μM range. The binding may occur in 
mM range but can not be determined with ITC due to the limitations in ITC which allows to measure 
affinities in μM range. 
Model: OneSites
Chi2/DoF = 762.8
N = 1.00 / 0
K = 3.48E3 / 934
∆H = -4543 / 988.1
∆S = 1.22
Model: OneSites
Chi2/DoF = 8873
N = 1.00 / 0.0715
K = 6.32E4 / 1.35E4
∆H = -3818 / 430.8
∆S = 9.37
Model: OneSites
Chi2/DoF = 1.014E4
N = 1.00 / 0.0720
K = 4.70E4 / 8.28E3
∆H = -6314 / 712.1
∆S = 0.551
A) B) C)
 
Fig. 4.14 ITC measurements with KKKDRSIWWV 
A) 300 μM peptide was injected into the cell containing 30 μM ∆N-HtrA1S328A. B) 300 μM peptide was injected into the cell containing 30 
μM methylated ∆N-HtrA1S328A. C) 300 μM peptide was injected into the cell containing 30 μM HtrA1-protS328A. For evaluations the 
number of binding sites was fixed to N = 1; Kd = 1/K. 
 
It would be interesting to evaluate the activation mechanism of HtrA1 as so far little is known. In 
analogy to the bacterial HtrAs the identified peptide which binds to the PDZ domain of HtrA1 would 
be a good candidate to further test the ability of this candidate peptide to activate HtrA1 (4.4.4) and 
/or to stabilize the PDZ domain in co-crystallization trials (4.7.4.2). Taken together the peptide 
KKKDSRIWWV is the first candidate for a peptide found via ITC to bind to the PDZ domain of HtrA1. It 
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would be interesting to do additional binding studies with the isolated PDZ domain of HtrA1 to 
confirm the results. Furthermore substitutions of amino acids at the C-terminus of the peptide would 
highlight the important residues for binding and would provide a detailed view into the binding 
mode. 
4.4 Proteolytic activity of HtrA1 
To characterize the proteolytic activity of HtrA1 ß-casein cleavage assays as well as assays with a 
chromogenic pNA-substrate were carried out. All assays were done with ∆N-HtrA1 and HtrA1-prot. 
4.4.1   ß-Casein degradation 
Time dependent degradation of ß Casein was followed on SDS-PAGE. Both HtrA1 variants degraded 
ß-casein highly efficient within 2 min (Fig. 4.15). The assay showed that the protease domain on its 
own retained proteolytic activity and can be considered to be as active as the wild type protein. This 
is in contrast to E. coli DegP and DegS, where the PDZ domain influences catalytic activity. The PDZ 
domain of HtrA1 seems to be dispensable for enzymatic activity. Despite the fact that full length 
casein is degraded equally fast, the subsequent cleavage of the casein degradation products is 
significantly faster with PDZless HtrA1 (Fig. 4.15).  
The degradation products occurring in the ß-casein assay are similar for both HtrA1 variants, showing 
no influence of the PDZ domain on the overall size of the products. 
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Fig. 4.15 ß-casein degradation by ∆N-HtrA1 and HtrA1-prot 
Time dependent degradation of ß-casein was followed on SDS-PAGE showing that the substrate is efficiently degraded by HtrA1. 10 μM 
HtrA1 was incubated with 170 μM ß-casein at 37°C for the time points indicated and subjected to SDS PAGE followed by Coomassie blue 
staining. Blue boxes mark degradation products which occure during cleavage and are faster processed with HtrA1-prot. 
 
To test if methylated ∆N-HtrA1 retained proteolytic activity this assay was performed in comparison 
to non-methylated ∆N-HtrA1. Methylated HtrA1 shows slightly decreased activity (Fig. 4.16). It can 
be concluded that methylation does not alter the activity towards ß-casein. Further tests were done 
with pNA as substrate as shown in 4.4.2. As expected, the methylated variant of ∆N-HtrA1 runs 
slightly higher in SDS-PAGE underlining that methylation occured. 
HtrA1
Time (min)        0      1      2      5      10      0     1   2      5     10     
∆N-HtrA1            ∆N-HtrA1 (meth)
Casein
Casein
deg. 
products
 
Fig. 4.16 Comparison of ß-casein degradation for methylated and not methylated ∆N-HtrA1 
10 μM HtrA1 was incubated with 170 μM ß-Casein and samples were incubated for the time points indicated and loaded on SDS-PAGE 
followed by Coomassie blue staining. The methylated (meth) protein runs slightly higher due to methylated lysines. ß-Casein is degraded 
equally fast.  
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4.4.2 pNA – Assays   
ß-casein assays have limitations because continuous measurements are not possible and analysis by 
SDS-PAGE is error prone. To overcome the disadvantages and to have the possibility to calculate 
specific activities of HtrA1 a pNA assay was established. Serine proteinase activity of the enzyme was 
measured by the release of p-nitroanilidine (pNA) from a peptide substrate. Several pNA´s available 
were tested and two could be taken for final measurements as they were processed by HtrA1.  
VFNTLPMMGKASPV-pNA was derived from the DegS substrate RseA and AC-FANQHLCGSHLVEA-pNA 
was derived from insulin-ß chain. Increasing release of pNA was monitored by spectrophotometry at 
405 nm.  
The pNA assays with the synthetic substrates shows that the rate of the degradation is affected 
slightly by deleting the PDZ domain suggesting that the PDZ domain does not contribute significantly 
to the enzymatic activity of HtrA1. 
In figure 4.17 a pNA assay is shown for the wt of ∆N-HtrA1, methylated ∆N-HtrA1 and HtrA1-prot 
with the substrate VFNTLPMMGKASPV-pNA. The methylated protein as well as the HtrA1-prot 
showed decreased activity towards the substrate. After 60 min the absorbance at 405 nm is approx. 
0.28 for ∆N-HtrA1 and 0.2 for methylated ∆N-HtrA1 and for HtrA1-prot.  
 
 
Fig. 4.17 pNA assay for different variants of HtrA1 
10 μM wt ∆N-HtrA1, methylated ∆N-HtrA1 and HtrA1-prot were incubated with 500 μM pNA-substrate at 37°C. The absorbance at 405 nm 
was measured continuously and plotted against the time. 
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4.4.3 Inhibition of HtrA1 
To test if the proteolytic function of HtrA1 can be inhibited, several boronic acid-based or chloro 
methyl ketone-based inhibitors were tested in ß-casein and pNA assays as they were describe as 
potential serine protease inhibitors (Kettner and Shenvi 1984). Inhibition could be observed by the 
use of the boronic acid derivative DPMFKLboroV as an inhibitor in a ß-casein degradation assay. At 10 
fold molar excess inhibition could be observed as judged by SDS-PAGE (Fig. 4.19). Complete inhibition 
was achieved in the presence of a 42 fold molar excess of the inhibitor (not shown). The assay was 
carried out with methylated protein as an identified inhibitor should be taken for co-crystallization. 
The tested CMK inhibitor did form aggregates with HtrA1 (data not shown) and was therefore not 
considered for co-crystallization trials.  
Taken together the peptide inhibitor was identified as one potent inhibitor and was subsequently 
tested for co-crystallization. 
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Fig. 4.18 Inhibition of ∆N-HtrA1 with DPMFKLboroV peptide 
∆N-HtrA1 was incubated with increasing amounts of the peptide inhibitor at 37°C. Molar ratios are indicated. Samples were taken after 10 
min and subjected to SDS PAGE followed by Coomassie blue staining 
 
4.4.4 Proteolytic activity in the presence of the peptide KKKDSRIWWV 
The ligand KKKDSRIWWV (identified by ITC) was tested in ß-casein and pNA assays for the ability to 
activate HtrA1. Both assays show a minor activation of HtrA1. The activated wt protein degrades ß-
casein completely within 8 min while the wt protein without peptide needs more than 10 min (Fig. 
4.19). Although full length ß-casein is degraded equally fast with or without peptide, the regulatory 
effect can be seen for the occurring degradation products (see blue box on SDS-PAGE). Here the 
accelerated degradation is obvious when the peptide is added.  
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Fig. 4.19 Activation of ∆N-HtrA1 by KKKDSRIWWV 
Incubation of ∆N-HtrA1 with peptide KKKDSRIWWV activates degradation of ß-casein. ß-casein was incubated with 10 μM HtrA1 with and 
without KKKDSRIWWV. Samples were taken at the time points indicated and subjected to SDS-PAGE following Coomassie blue staining. 
 
The result is similar to the observed result for PDZless HtrA1 (Fig.4.16) which is degrading casein 
degradation product significantly faster. Activated ∆N-HtrA1 seems to act similar to PDZless HtrA1 
(Fig. 4.16). The same assay was performed for HtrA1-prot, but no activation could be determined 
(data not shown).  
A possible activation with the peptide KKKDSRIWWV was also investigated in a pNA assay. The assay 
was performed with different peptide concentrations ranging from 5 μM to 250 μM as the Kd of the 
peptide was determined determined to be 13.4 μM. 5 μM peptide is able to increase ∆N-HtrA1 
activity up to 30% (Fig. 4.21) and ∆N-HtrA1 activity with 20% but did not activate HtrA1-prot. Higher 
peptide concentration than 10 μM did show only minor activation effects which could be explained 
with the reduced solubility of the peptide.  
Based on this assay the specific activity of HtrA1 could be calculated as indicated in the following 
table: 
 
Tab. 4.3 Specific activities of ∆N-HtrA1 and HtrA1-prot 
  ∆Abs = m ∆c/min 
Kcat  
(μM  x min-1) 
spec. activity (pmol x 
min-1 x mg-1) 
∆N-HtrA1 0,0036 1,36E-06 1,36 37,06 
∆N-HtrA1 + 5 μM pep 0,0047 1,78E-06 1,78 48,38 (30%) 
∆N-HtrA1 + 10 μM pep 0,0043 1,63E-06 1,63 44,10 
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  ∆Abs = m ∆c/min 
Kcat  
(μM  x min-1) 
spec. activity (pmol x 
min-1 x mg-1) 
∆N-HtrA1 + 20 μM pep 0,0044 1,67E-06 1,67 45,20 
∆N-HtrA1 + 50 μM pep 0,0036 1,36E-06 1,36 37,01 
∆N-HtrA1 (meth) 0,002 7,58E-07 0,76 19,94 
∆N-HtrA1 (meth) +  5 μM pep 0,0024 9,09E-07 0,91 23,92 (20%) 
HtrA1-prot 0,0023 8,71E-07 0,87 34,99 
HtrA1-prot + 5 μM pep 0,0024 9,09E-07 0,91 36,51 
Abs = absorbance, ∆Abs = m; ∆c = ∆Abs / (8800 M-1 x cm-1 x 0.3 cm); Kcat = ∆c x 106, specific activity in pmol= ∆c/molecular mass (Da) x 
1012 pep = KKKDSRIWWV 
 
In contrast to ∆N-HtrA1, HtrA1-prot can not be activated with the peptide. This is in agreement with 
the observed ITC data which showed binding of the peptide only in presence of the PDZ domain. And 
with the ß-casein assays which did not show activation for HtrA1-prot when incubated with the 
peptide. Taken together these data imply an allosteric regulatory role for the PDZ domain concerning 
the activity of HtrA1. 
4.4.5 Activation through oligomerization in the presence of model substrates 
As shown in 4.2.1.1 there are indications that HtrA1 is able to oligomerize in the presence of 
unfolded substrate. Thus the influence of the presence of unfolded substrates on the proteolytic 
activity of HtrA1 was studied in a pNA assay. The assay was performed at 42°C as citrate synthase 
starts to aggregate at this temperature. The specific activity for HtrA1 was calculated at the steepest 
part of the curve shown in figure 4.20. ∆N-HtrA1 can be activated 2.7 fold when the release of pNA is 
measured in the presence of unfolded CS (Fig. 4.20 A). Consistently with the observed data from SEC 
HtrA1-prot can also be activated by binding unfolded substrates in the same order of magnitude. 
Interestingly no activation could be observed if the assay was performed in pH 7.5, a condition were 
no multimer can be observed in SEC (Fig. 4.12 C) and HtrA1 shows very low proteolytic activity (data 
not shown). 
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Fig. 4.20 pNA assay in presence of unfolded substrate citrate synthase 
A) Activation of ∆N-HtrA1 and HtrA1-prot by unfolded citrate synthase is shown. Specific activity of ∆N-HtrA1 or HtrA1-prot was 
determined using VFNTLPMMGKASPV-pNA as a substrate in the presence and absence of heat denatured citrate synthase at 42°C. B) No 
activation was observed if the assay was performed at pH 7.5. 
 
From the assay it can be speculated that oligomerisation might be a mechanism of activation 
independent of the PDZ domain as both variants show increased activation. 
Results           83 
 
4.5 Complete digests of model substrates 
4.5.1 Complete digests of citrate synthase and malate dehydrogenase 
In order to identify the specificity of HtrA1 complete substrate digests heat denatured malate 
dehydrogenase (MDH) and heat denatured citrate synthase (CS) were performed. To reveal the 
identity of the peptide products they were analysed by mass spectrometry. Substrates were added in 
excess amounts and the reaction was incubated for 4 hrs or over night and followed in parallel by 
SDS-PAGE (not shown). Not digested substrate and HtrA1 itseld were precipitated with acetone. The 
complete digests were done with ∆N-HtrA1 and HtrA1-prot. The published primary sequences of the 
substrates were used to assign the molecular weights after mass spectrometry to the corresponding 
peptides. With both proteins a large number of different peptides were generated. However not all 
the peptides could have been detected by this method, where it was attempted to determine the 
composition of a complex mixture in a single step. Apparently, some peptides whose existence would 
be caused by a present neighbouring fragment were not detected. This is illustrated by the 
representative cleavage pattern of the citrate synthase (Fig. 4.21).  
 
 
Fig. 4.21 Cleavage pattern of citrate synthase 
Depicted are the peptides derived by degradation of heat denatured CS with ∆N-HtrA1. 
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Furthermore not all peptides were detected with the same reliability (data not shown). Especially 
larger peptides, containing more than 30 amino acid residues were rarely detected. However the 
vast majority was clearly detected, thus statistical parameters about the reliability of individual 
peptides were omitted in the analyses. This was also done with respect to the fact, that there is no 
clear cut-off value, which would allow a differentiation between a ‘good’ and a ‘bad’ peptide. In 
summary there were 206 peptides identified for ∆N-HtrA1, 67 for MDH and 94 for CS. For HtrA1-prot 
60 peptides for MDH and 124 peptides for CS were detected. The evaluation of MDH and CS showed 
that the vast majority of the residues at the carboxy-terminus of the peptide fragments (P1 position) 
are small hydrophobic amino acids like leucine, valine, alanine and threonine (Fig. 4.22). This is in 
good agreement with previous studies for DegP (Krojer et al. 2008, Jones et al. 2002, Kolmar et al. 
1996). Additionally a number of methionine, serine and isoleucine residues were identified, but other 
amino acids were only found occasionally.  
 
Fig. 4.22 Preferences for small hydrophobic residues at P1 site 
Sequence analysis of the identified peptides resulting from citrate synthase and malate dehydrogenase degradation revealed the specificity 
of HtrA1 for the P1 position of substrates. The observed P1-occurrences of the 9 most frequently identified amino acids are shown. Black 
bars indicate the results for ∆N-HtrA1, blue bars for HtrA1-prot. 
 
Further analysis of the digestion pattern was conducted to characterize possible preferences for 
certain amino acids in the P1´ position (the position of the leaving group of the scissile bond 
according to the Schechter-Berger notation). The results of the analysis are shown in figure 4.23. 
Here the situation is not as clear as for the P1
 
position. Although the majority of the amino acids 
belong to the class of small residues (S, A, V, L) a significant number belongs to bigger residues like 
lysine and tyrosine.  The charge of the residues seems to be irrelevant.  
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Fig. 4.23 Preferences at P1´site 
Sequence analysis of the identified peptides resulting from citrate synthase and malate dehydrogenase degradation revealed the 
preference of ∆N-HtrA1 for the P1´ position of substrates. The observed P1´-occurrences are shown.  
4.5.2 Length distribution of degradation products 
To further characterize the proteolytic activity of HtrA1, the length distribution of the degradation 
products for ∆N-HtrA1 and HtrA1-prot were analyzed. The majority of the generated peptides had a 
length between 6 and 30 residues for both proteins. Fragments longer than 25 residues were only 
occasionally detected and these peptides were most often of little reliability. Furthermore, no 
peptides shorter than six amino acid residues were found. In principle peptides shorter than six 
amino acids could have been produced but were not detected due to the identification technic.  
 
Fig. 4.24 Length distribution of peptide products generated in MDH and CS digests 
Product sizes of complete digests of citrate synthase and malate dehydrogenase with wt ∆N-HtrA1 and HtrA1-prot were determined by 
mass spectrometry. The identified products were counted and plotted. The blue curve shows the results for HtrA1-prot, the black curve for 
∆N-HtrA1.  
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Plotting the length of the peptide products (Fig. 4.24) revealed that the average length of the 
peptides was 15 residues for ∆N-HtrA1 and 10 residues for HtrA1-prot. This significant difference 
implicates a role for the PDZ domain in shaping cleavage products. 
4.6 Liposome binding assay 
∆N-HtrA1 and HtrA1-prot were further characterized in liposome binding assays. The bacterial 
homolog DegP was shown to bind via its PDZ domains to liposomes. Thus liposome binding assays 
were conducted for ∆N-HtrA1 and HtrA1-prot to determine if the human homolog displays a similar 
behaviour and to study the role of the PDZ domains. Additionally the human homolog HtrA2 (lacking 
the first 133 N-terminal residues) was tested. Brain extracts from bovine were incubated with ∆N-
HtrA1, HtrA1-prot and mature HtrA2 (Fig. 4.25).  
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Fig. 4.25 Liposome binding assay 
Co-sedimentation assays show binding of ∆N-HtrA1 and HtrA1-prot to bovine brain liposomes. Titration experiments were carried out with 
a fixed amount of HtrA1 and HtrA2 (0.1 mg/ml) and increasing concentrations of liposomes as indicated. HtrA1 and HtrA2 were incubated 
with liposomes 10 min at 37°C and ultra centrifuged for 30 min. “S” and “P” refer to proteins present in the supernatant or pellet after 
centrifugation. A) ∆N-HtrA1S328A B) HtrA1-protS328A C) ∆N-HtrA2SA D) The electrostatic potential of the protease domains of HtrA1 and HtrA2 
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was calculated with PYMOL and mapped on the molecular surface of the particle. Red indicates negatively charged regions, blue positively 
charged regions. The protease domain is shown as a trimer in top and bottem view. 
It could be shown that both HtrA1 proteins co-sediment with liposomes as the amount of protein 
increases in the pellet fraction with increasing amounts of liposomes. HtrA2 does not show binding 
to liposomes. 
The obtained results indicate that the PDZ domains are dispensable for binding to liposomes as no 
differences between ∆N-HtrA1 and the protease domain could be observed. Analysing the surface 
potential of the protease domain of HtrA1 and HtrA2 identifies more positive charged residues for 
HtrA1 than for HtrA2 (Fig. 4.25 D) which could explain why HtrA2 does not co-sediment with 
liposomes.  
4.7 Protein crystallization 
4.7.1     Crystallization of ∆N-HtrA1S328A 
4.7.1.1 Screening for initial crystallization conditions   
Initial crystallization trials were done in 96 well plates by using the commercially available Hampton 
Research Screens Index, Crystal 1 & 2, Membfac/Peg/Ion, Cryo 1 & 2, Wizard and from Jena 
Bioscience JBS 1 - 10. Initial screening was done first with the non methylated ∆N-HtrA1S328A and 
finally with the methylated mutant protein as non methylated protein did not produce a single hit in 
any screen. Crystalization trials were setup with the sitting-drop vapour diffusion method at 19°C and 
the drop ratio was 1:1 and 1:2, i.e. 0.1 μl of protein and 0.1 μl or 0.2 μl of reservoir solution in 96-well 
plates. The concentration of the protein solution was approx. 30mg/ml for all different crystallization 
trials. After approx. one week small cubic crystals appeared at 19°C (Fig. 4.26).  
 
Fig. 4.26 Crystals from the initial crystallization condition in 96 well plates  
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Crystallization condition: 0.5 M (NH4)2SO4, 0.1 M Na-citrate pH 5.4, 1 M LiSO4 
The crystals were stained with Izit (Hampton Research) to confirm that these crystals are made of 
protein. Interstingly, the same condition did not give any crystals for the methylated protein. 
Subsequently this condition was used for further fine-screening to obtain bigger crystals for testing 
their diffraction potential at the in-house x-ray generator.  
4.7.1.2 Optimization 
In order to grow bigger and more compact crystals, suitable for data collection, the components of 
the crystallization solution were varied, i.e. different buffer substances, different pH values and 
different drop ratios were tested. Moreover, a variety of additives, i.e. salts like MgCl2 or organics like 
ethanol were added to the initial crystallization solution with a drop ratio of 2 μl of protein solution, 
0.3 μl additive and 1 μl of reservoir solution. The final crystallization condition yielded compact cubic 
crystals grown in 24-well plates (Fig. 4.27). 
 
Fig. 4.27 Optimized crystals in 24-well plates 
Crystallzation condition: 0.6 M (NH4)2SO4, 0.1 M Na-citrate pH 5.4, 5.6, 5.8, 6.0 and 6.3, 1 M LiSO4. Drop ratio:   2 μl HtrA1S328A (30 mg/ml) 
and 1 μl crystallization solution. 
 
4.7.2 Crystallization of wt ∆N-HtrA1 
The methylated wild type protein was crystallized in exactly the same refined conditions as described 
for the mutant version directly in 24-well plates and yielded crystals with comparable size and shape 
after 2 to 3 days.  
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4.7.2.1 Co-crystallization of wt ∆N-HtrA1 with a boronic acid inhibitor 
The catalytically active methylated protein was furthermore co-crystallized with the DPMFKLboroV 
peptide containing a boronic acid group at the C-terminus. The aim was to lock the protease in an 
active conformation as boronic acids are described to bind covalently to the active site serine 
(Kettner and Shenvi 1984). The Ki of the boronic inhibitor was 2.6 µM as determined by using 
VFNTLPMMGKASPV-pNA as a substrate in an HtrA1 cleavage assay (personal communication) and 
inhibited ∆N-HtrA1 in a ß-casein cleavage assay as shown in 4.4.3. Inhibition was only achieved in the 
presence of a 10 fold molar excess of the inhibitor. This was taken into consideration when setting up 
crystal trials. The peptide inhibitor was co-crystallized in a 1:2 molar and 1:20 molar ratio and 
crystallization plates were set up with the same conditions as for the inactive mutant in 24-well 
plates. Successful crystallization was only achieved with 2 mM inhibitor concentrations. Quasi 
crystals appeared in the 1:20 molar ratio set up, showing no sharp edges and were not taken for 
refinement. Crystals for the 1:2 molar ration appeared after 2 to 3 days but no single crystals could 
be obtained as they were growing into each other (Fig. 4.28). They diffracted to 8 Å. 
4.7.2.2 Optimization of crystal quality with seeding 
Co-crystallization with the DPMFKLboroV peptide yielded crystals in the same conditions as 
mentioned for ∆N-HtrA1S328A. Nervertheless these crystals had to be refined and the method of 
choice was seeding. Seeding allows one to grow crystals in the metastable zone. Crystallization in this 
zone provides control, reproducibility and an improved likelihood of a successful crystallization 
experiment. By placing a seed or solution of seeds in a drop which is saturated to the metastable 
zone, one can use the seeds to grow larger single crystals. By controlling the number of seeds 
introduced into the drop, one can control the number of crystals grown. Different dilutions of seeds 
were tested and crystal growth took 4 weeks yielding cubic single crystals with good diffraction 
properties.  
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Fig. 4.28 Crystals can be improved by seeding 
Drop ratio: 2 μl ∆N-HtrA1 incubated with inhibitor, 1 μl reservoir, 0.3 μl seeds 10-5 and 10-6 diluted in reservoir. Seeds were derived from 
co-crystals of wt HtrA1 and inhibitor. 
4.7.3 Crystallization of HtrA1-prot 
Crystallization of the protease domain of HtrA1 was done using the initial screens described for ∆N-
HtrA1 crystallization with non methylated mutant protein. The protease domain crystallized in many 
different conditions and crystals were found in many different shapes like illustrated in examples in 
the figure below.  
 
 
Fig. 4.29 HtrA1-protS328A crystals from initial screens 
Hexagonal plates, stars bipyramidal and cubic crystals were observed in many different conditions in initial screens. Fine screened 
crystallization condition contained 0.1 M Na-acetate pH 4.6 and 2 M (NH4)2PO4. 
 
 
Hexagonal and bipyramidal crystals were fine screened (see legend Fig. 4.29) and datasets for the 
bipyramidal crystals were collected and analysed. 
All crystallization conditions had in common that the pH was around 5. HtrA1 was found to be not 
active at that low pH (data not shown) and conclusively the solved structure showed the protease 
domain in the inactive conformation. To promote the active conformation crystals were shifted from 
a low to a higher pH. There was no possibility to to collect x-ray diffraction data for these shifted 
crystals as they suffered too much in the new reservoir and broke. 
Seeding 
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4.7.4 Further improvement of HtrA1 crystals 
4.7.4.1 Improvement of diffraction properties 
The final electron density maps showed no clear density for the PDZ domain which had therefore to 
be omitted from the model. Nevertheless the maps for ∆N-HtrA1 showed a lot of additional density 
and the PDZ domain was tried to model in without success. Given the possibility that the PDZ domain 
is too flexible and stabilization could help to visiualize the domain, different optimization strategies 
were applied. The first possibility is to increase the resolution to be able to model the PDZ domain. 
Therefore strategies included crystallization at 4°C, shifting of crystals from 19 to 4°C as this might 
stabilize the PDZ domain and crystallization in hanging drops. The hanging drop method differs from 
the sitting drop method in the vertical orientation of the protein solution drop within the system. 
Nevertheless crystallization in hanging drops did not improve the resolution. Crystallization at 4°C 
was successful but gave neither a different unit cell nor better resolution. The crystals shifted from 
19°C to 4°C kept growing for weeks and defracted to 2.5 Å. The structure was solved by moleculare 
replacement (MR) with HtrA1. Still these datasets showed no clear density for the PDZ domain.  
4.7.4.2 Co-crystallization of ∆N-HtrA1S328A with peptide KKKDSRIWWV  
Another strategy to stabilize the PDZ domain or to decrease the flexibility was the co-crystallization 
of ∆N-HtrA1S328A with the peptide KKKDSRIWWV which was found to bind to the PDZ domain by ITC 
measurements. Co-crystallization was carried out in a 1:1 molar ratio using 900 μM ∆N-HtrA1 and 
900 μM peptide (i.e. > 50x Kd of the peptide) and crystals could be observed. They diffracted poorly 
and it was not possible to improve them. Crystals were also soaked with peptide. Some of the soaked 
crystals started to “melt” but one dataset could be collected. The crystal diffracted to 2.9 Å with very 
similar unit cell dimensions as for the crystals without peptide. The structure was solved by 
molecular replacement with the protease domain of HtrA1S328A. The initial model showed no density 
for the PDZ domain. 
4.7.4.3 Crystallization of selenomethionine substituted wt ∆N-HtrA1 
HtrA1 contains six methionine residues one as the starting amino acid, four in the PDZ domain and 
one in loop L3 which is a mechanistically important loop. Methionine can be substituted by 
selenomethionine which anomalous scattering properties can be exploited for solving the 
crystallographic phase problem. The anomalous dispersion of the selenium atoms can be taken to 
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calculate initial phases. The crystals of the ∆N-HtrA1 wild type co-crystallized with the inhibitor 
peptide showed the protease domain in the active conformation. One characteristic of this 
conformation is that loop L3 and subsequently the methionine as well as the side chain are present in 
an ordered conformation. Semet-protein was successfully expressed, purified and co-crystallized 
with the inhibitor peptide. The dataset could be refined to 2.5 Å and the presence of selenium in the 
protein could be confimred by an absorption edge scan before proceeding with the MAD diffraction 
experiment. An X-ray absorption spectrum of the crystal was collected near the selenium K 
absorption edge by measuring the fluorescent signal perpendicular to the beam during an energy 
scan performed at the ESRF. Only very weak anomalous signal was detected and the position of the 
selenomethionine could not be determined. 
4.8 Crystal structure of HtrA1 
4.8.1 Data collection and structure determination 
Data collection experiments have been performed at beamline ID 14-4 at the ESRF (Grenoble, 
France) to collect datasets for ∆N-HtrA1S328A and HtrA1-prot.  The crystals were briefly soaked with 
cryobuffer before flash frozen in liquid nitrogen. The experiments were made with native crystals. All 
diffraction data were processed and scaled with the programs DENZO and SCALEPACK. All crystals of 
∆N-HtrA1 belonged to the trigonal space group H3 with one ∆N-HtrA1 monomer in the asymmetric 
unit and unit cell constants of a = 108 Å b = 108 Å c = 113 Å and α = 90, ß = 90 and γ = 120. Data of 
improved ∆N-HtrA1-inhibitor crystals were collected at beamline X06SA at the SLS (Zurich, Swiss) at λ 
= 0.9724 Å using a Pilatus detector (Dectris). The crystals belonged to spacegroup H3 with slightly 
different cell constants of a = 105.965 Å, b = 105.965 Å, c = 118.336 Å. 
Crystals of the protease domain belonged to the tetragonal spacegroup P43212 with unit cell 
constants of a = 153.671 Å, b = 53.671 Å, c = 89.835 Å containing three molecules per asymmetric 
unit. A summary of the data collection statistics is given in Table 4.4.  
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Tab. 4.4 Summary of data collection statistics 
Data Collection ∆N-HtrA1 + inhibitor ∆N-HtrA1S328A  HtrA1-prot 
Space Group H3 H3 P43212 
Unit Cell Parameter Å 
105x105x118 
90x90x120 
108x108x113 
90x90x120 
153x153x89  
90x90x90 
Resolution Å1 50 - 2.75 50 - 2.75 50 – 3.0 
Completeness % 99.9 (99.9) 95.7 (87.5) 91 (89.1) 
Rsym %2 7.2 (46.3) 6 (39.5) 10.2 (62.5) 
I/sigma (I) 6.4 (3.9) 9.3 (3.9) 27.7 (25.3) 
Redundancy 4.8 (5.1) 3.3 (3.3) 2.0 (1.7) 
Tab. 4.4 Summary of data collection statistics 1Numbers in parentheses refer to the highest resolution shell. 2Rsym is the unweighted R-
value on I between symmetry mates. Co-crystals with ∆N-HtrA1 and inhibitor showed the active conformation, the SA mutant of ∆N-HtrA1 
and the protease domain showed the inactive conformation. 
 
4.8.2 Structure solution 
The structure for ∆N-HtrA1S328A and for HtrA1-prot were determined by molecular replacement (MR) 
using the program Phaser of the CCP4 package (CCP4, 2002) and the protease domain (residues 140 - 
340) of human HtrA2 (Protein Data Bank ID 1LCY) as a search model. Human HtrA2 shows the highest 
similarity to human HtrA1. Electron density maps based on the coefficients 2Fo-Fc and 3Fo-2Fc were 
calculated from the phases of the initial model. 
The structure of wild type ∆N-HtrA1 in complex with the inhibitor peptide was solved as well by MR 
with the protease domain of ∆N-HtrA1S3298A as a search model. Clear, additional density was observed 
in the active site and allowed insertion of the entire inhibitor molecule except the side chains of the 
P3-lysine and the P7-aspartate, which were replaced by alanine. 
4.8.3 Model building and refinement 
The program O was used for model building. For the ∆N-HtrA1S328A structures just one molecule was 
present in the asymmetric unit (AU). The electron density map was of good quality in the protease 
region but showed no clear density for the PDZ domain which had to be excluded from the model 
(residues 371 to 480). Additionally, the residues 158 to 160 and 301 to 314 (Loop L3) could not be 
fitted into the electron density. The current model has an R-factor of 25.43% (RFree=28.52%).  
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For the ∆N-HtrA1-Inhibitor crystals also one molecule per asymmetric unit was present. During 
refinement of the HtrA1 inhibitor complex, clear electron density developed for one inhibitor 
molecule within the active site of the protein. In contrast to ligand-free HtrA1, the entire protease 
domain was well defined. Especially for the proteolytic site that underwent pronounced 
conformational changes remodeling was carefully inspected. In these maps, residues 158 - 159 and 
371 - 480 had to be omitted from the model due to high flexibility. The current model has an R-factor 
of 22.38% (RFree=27.82%) 
For HtrA1-prot three molecules were present per AU which will be referred to as molecule A, B and 
C. Protein segments including residues 158–160, 301–314 (loop L3) and 365-373 were hardly visible 
or invisible and were therefore omitted from the model. The stereochemistry of all three models was 
validated with PROCHECK. The refinement statistics are summarized in table 4.5. 
 
Tab. 4.5 Refinement statistics 
 
∆N-HtrA1 + inhibitor  
active 
∆N-HtrA1S328A 
inactive 
HtrA1-prot 
Resolution Å 20 – 2.75 20 - 2.75 20 – 3.2 
Rcryst/Rfree1 22.38 / 27.82 25.43 / 28.52 25.36 / 27.95 
Number of reflections 
Rwork/Rfree 
12208 / 651 11473 / 603 16725 / 900 
Number of protein atoms / 
ligand atoms   (C / N / O / S / B) 
1013 / 275 / 304 / 1 
35 / 7 / 8 / 1 / 1 
946 / 249 / 281 914 / 239 / 266 
Average B-factor protein / 
ligand Å2 
70.18 / 111 63.2 56.55 
Root mean square deviations    
Bond length Å / angles Å / 
bonded Bs Å2 
0.0075 / 1.5 / 1.6 0.008 / 1.46 / 1.7 0.009 / 1.48  / 1.6 
Ramachandran statistics %    
Most favoured / additionally 
allowed / 
generously allowed / 
disallowed region2 
71 / 27.4 / 0.5 / 0.0 81.5 / 17.3 / 1.2 / 0.0 77 / 21.3 / 1.4 / 0.2 
Tab. 4.5 Refinement statistics 1Rcryst = Σhkl | |Fobs (hkl)| - k |Fcalc (hkl)| | / Σhkl |Fobs (hkl)| for the working set of reflections; Rfree is the R-value 
for 5% of the reflections excluded from refinement. 2The stereochemistry of the model was validated with PROCHECK. 
 
4.8.4 Tertiary structure of the inactive HtrA1 
Similar to other members of the trypsin family, the protease domain of HtrA1 is formed by two 
perpendicular ß-barrel lobes (β1−β6 and β7−β12) with an N-terminal and C-terminal helix. The 
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catalytic triad is located in the crevice between the two lobes (Fig. 4.30). The activation domain of 
the protease constituted by the active site loops L1, L2 and LD (nomenclature according to Perona 
and Craik 1995 and Krojer et al. 2008) is severely distorted impeding the proper adjustment of the 
catalytic triad, formation of the oxyanion hole and the S1 specificity pocket. For example, ß3 
following the active site His220 is, causing an improper localization of His220 with respect to Asp250 
and Ser328 (Fig. 5.3). Therefore, the protease domain is present in an inactive conformation. 
Furthermore, loop L3 that in HtrA proteases was too flexible to be traced in the electron density. A 
flexible loop L3 and in addition a misarranged activation domain are typical features of inactive HtrA 
protease states as previously observed in DegP and DegS (Krojer et al. 2002,  Wilken et al. 2004). 
 
H220
D250 A328
N-terminus
H220
D250
A328
LD
L2
L3
L1
A) B)
 
Fig. 4.30 HtrA1 in an inactive conformation 
A) The active site is sandwiched between two ß-barrel lobes building up the HtrA1 protease domain. Residues of the catalytic triad are 
labelled and shown in ball and stick representation. Serine 328 is replaced by alanine. B) Mechanistically important loops are labelled. Note 
that loop L3 is not ordered and had to be omitted from the model. 
4.8.4.1 Assembly of the trimer 
Size exclusion chromatography revealed an apparent molecular mass of 120 kDa suggesting the 
presence of HtrA1 trimers (Mw 36.8 kDa) in solution. Consistently, in the crystals, three monomers 
are arranged around a crystallographic three-fold axis with the N-termini located to the opposite 
face as the active site. The PDZ domains were not defined by electron density.  
Homotrimerization is mediated exclusively by the protease domain, in particular by N-terminal 
residues and ß-sheet interactions. At the top, three conserved residues, Tyr169, Phe171 and Phe278 
from each monomer, stack against each other. They form a hydrophobic, aromatic cylinder at the 
interface of the HtrA1 monomers (Fig. 4.31). This interaction is further stabilized by H-bonds within 
ß-sheet 8 from each monomer and the side chain of Asp320 (Fig. 4.32). The side chain of Asp320 
forms inter- and intramolecular H-bonds to the main chain amid of Ile296 and Thr294* in the 
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neighboring monomer. Furthermore, ß-sheet 8 from each monomer forms three hydrogen bonds to 
the adjacent monomer. Consistently, the HtrA1 trimer is remarkably stable in solution, even at low 
µM concentrations (e.g. 1.5 µM) no HtrA1 monomers could be detected by SEC.  
 
 
Fig. 4.31 Homotrimer formation in HtrA1 by conserved hydrophobic residues 
A) Cartoon representation of the homotrimer from the top. The individual monomers are coloured differently. B) Close up view of the 
trimer interface. Residues Tyr169, Phe171 and Phe278 of each monomer form ring stacking interactions to build the homotrimer. These 
residues are presented in a ball-and-stick model. 
 
T299*
S298*
I296*
N290
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T293
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T293*
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T291** V292**
T293**
 
Fig. 4.32 Homotrimerization is stabilized by serveral hydrogen bonds 
Residues are shown in ball and stick representation and labelled if they form hydrogen bonds to the neighbouring monomer. Residues of 
monomer 2 and 3 are indicated with * and **, respectively. Asp320 forms inter- and intramolecular hydrogen bonds thereby connecting 
two monomers. 
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4.8.5 Tertiary structure of the active HtrA1 
The catalytically active protein was co-crystallized with the DPMFKLboroV peptide containing a 
boronic acid group at the C-terminus. After molecular replacement with the protease domain of 
HtrA1 clear, additional density was observed in the active site and allowed insertion of the entire 
inhibitor molecule except the side chains of the P3-lysine and the P7-aspartate, which were replaced 
by alanine.  
 
 
P7
P6
P4
P2
P7
P6
L345
L309
P4
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P7
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L345
L309
 
Fig. 4.33 The inhibitor peptide DPMFKLboroV is bound to the active site 
A) Cartoon representation of the homotrimer shown from the bottom. Each monomer is coloured differently. The inhibitor peptide (blue) 
is bound to the active site. Inhibitor peptide and active site residues are shown in ball and stick representation. B) Stereo view. 2FoFc - 
electron density for the covalently attached inhibitor DPMFKLboroV, contoured at 1 sigma. The protease domain (green) and the inhibitor 
peptide are shown in ball and stick representation.  
A) 
B) 
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The inhibitor molecule is covalently attached to the active site Ser328 via the boronic acid group, 
forming a tetrahedral boronate complex (Fig. 4.33). The inhibitor undergoes numerous interactions 
with the protease domain. These interactions lead to a rearrangement of the active site loops (Fig. 
4.34) converting the protease from the resting into the active conformation. 
The active conformation was evident from the following observations: First, the active site residues 
His220, Asp250 and Ser328 reorient upon inhibitor binding and are now properly positioned to set up 
a functional catalytic triad. e.g. the interatomic distances between components of the His/Asp/Ser 
proton relay system are 2.65 Å between Asp250 and His220 and 2.87 Å between His220 and Ser328 
in the active conformation (Fig. 4.34 A) while they are for example 9.5 Å between His220 and Ala328 
in the inactive conformation. Second, loop L3 undergoes a disordered-order transition and is now 
present in a well-defined conformation contributing to a functional activation domain required for 
efficient protein cleavage. Third, a proper oxyanion hole is formed by the peptide stretch 325-327 
preceding the active site serine. Formation of the oxyanion hole is achieved by a peptide flip of 
Gly326 (loop L1: Ile322-Ile323-Asn324-Tyr325-Gly326-Asn327) allowing accommodation of the O¯ -
group of the boronic inhibitor. In addition, the inhibitor is captured by participating in a composite 
hydrophobic cluster that is constituted by Leu307, Leu309 and Tyr316 (loop L3), Leu345, Thr344 and 
P2-Leu, P4-Phe of the inhibitor (Fig. 4.34 B). 
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Fig. 4.34 Active conformation of HtrA1 
A) The protease domain in the active conformation. Residues of the catalytic triad are shown in ball and stick representation. H-bonds are 
indicated. Mechanistically important loops are labelled. Loop L3 is now in an ordered conformation interacting with the inhibitor peptide. 
B) Close up view of the interactions between protein and inhibitor showing the hydrophobic cluster. P1-Val points into S1 specificity 
pocket; P4-Phe and P2-Leu undergo hydrophobic interactions with Leu305, Leu 309 and Tyr316 in loop L3 and Leu345 as well as Thr344. 
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Moreover, the P1-valine of the inhibitor is deeply buried within the S1 specificity pocket, which is 
formed by the aliphatic side chain of Lys346 and the side chain of Ile323 (Fig. 4.35). In figure 4.37 the 
interactions between the inhibitor peptide and HtrA1 are summarized. 
 
Fig. 4.35 DPMFKLboroV undergoes numerous interactions with the HtrA1 protease domain 
Schematic view of interactions between protein and inhibitor was made with chemgraph. 1: P4-Phe and P2-Leu undergo hydrophobic 
interactions with HtrA1; 2, 3, 4: indicate hydrogen bonds to the backbone of HtrA1; 5: covalent binding of the boronic acid group to the 
carbonyl of the active site Ser328; 6: the P1-Val points into the S1 specificity pocket. In grey are the side chains of P3 lysine and P7 
aspartate depicted which have been replaced by alanine in the structure. 
1 
6 
2 
3 
4 5 
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5  Discussion 
5.1 HtrA1 can be over expressed in and purified from E. coli cells 
The N-terminus of HtrA1 comprises a Kazal-like inhibitory domain and an IGFBP-like domain 
containing 18 cysteines. So far these domains are uncharacterized as is was not possible to express 
and purify the full length protein in large amounts. Purification of the protein from insect cells 
resulted in small amounts not suited for crystallization (personal communication). It is very common 
for recombinant proteins expressed in E. coli to form insoluble, misfolded cytoplasmic complexes 
known as “inclusion bodies” (Mitraki and King 1989). Inclusion body formation is unpredictable but 
seems to increase in proportion to the size and complexity of the protein (LaVallie 2002). 
One useful strategy to express proteins in E. coli cells is the fusion to proteins like GST, MBP or 
thioredoxin which may enhance solubility of the target protein. Even though there are studies on the 
effects of different tags the mechanism behind the solubilizing effect remains unclear (Dyson et al. 
2004, Hammarström et al. 2006). In the case of thioredoxin, it has been proposed that it could exert 
its effect either by acting as a covalently linked chaperone (Berndt et al. 2008, Liu et al. 2007, Sun et 
al. 2007), aiding in protein folding, or as an oxidoreductase, which would catalyze the correct 
formation of disulfide bonds. Furthermore most proteins containing disulfide bonds require not only 
fusion to thioredoxin, but also expression in genetically modified E. coli strains having an oxidizing 
cytoplasm (e.g. Origami B(DE3) cells) (Peisley and Gooley 2007, Xiong et al. 2005,  Lauber et al. 2001,  
Lehmann et al. 2003). This would suggest that thioredoxin could also be catalyzing proper disulfide 
bond formation. Nevertheless the expression in fusion with thioredoxin was described for proteins 
containing Kazal-type inhibitory domains (Vitzithum et al. 2008, Lauber et al. 2001). In this work His-
tagged full length HtrA1 was not expressed in soluble form in BL21(DE3)pLysS cells, and only little 
expression was observed with expression in Origami B(DE3) cells as indicated by Western Blot 
analysis. However, a fusion construct comprising HtrA and a thioredoxin-tag showed dramatically 
improved expression in Origami B(DE3) cells. This suggests that thioredoxin promotes the solubility 
of HtrA1 by catalyzing proper disulfide bond formation.  
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To further investigate the folding status of full length HtrA1 different approaches could be 
considered. First of all it would be possible to map disulfide bonds and more easily to identify 
cysteines which are not involved in disulfide bond formation. Furthermore circular dichroism 
spectroscopy, a method to determine the secondary structure of proteins, could be applied to 
investigate the secondary structure of HtrA1. The N-terminus of HtrA1 was purified separately during 
this thesis and could be taken for these experiments in addition.  
As the N-terminus contains a kazal-like inhibitory motif, it would be interesting to discover its 
inhibiting ability towards trypsin-like proteases. Possible candidates would be proteases from the 
ECM as HtrA1 is predicted to be secreted to the ECM. To establish an assay to show the inhibition of 
HtrA1 towards other proteases would be in addition a proof for HtrA1 to be folded. 
Taken together, being able to express and purify full length HtrA1 from E. coli cells in large amounts 
offers for the first time the possibility to crystallize the protein in the future and to characterize it in 
detail. As the N-terminus shows an inhibitory motif for trypsin like proteases it would be interesting 
to assess the influence of this domain on HtrA1 itself as well as other trypsin like proteases especially 
in the ECM.  
5.2 Inactive conformation of HtrA1 
The basic building block for HtrA family members is a trimer as described for human HtrA2 (Li et al. 
2002), the protease domain of HtrA from Thermotoga maritima (Kim et al. 2003) as well as for DegS 
and DegP from E. coli (Wilken et al. 2004, Krojer et al. 2002) and the HtrA protease from M. 
tuberculosis (Mohamedmohaideen et al. 2008). Homotrimerization was also observed for HtrA1. 
Interactions between monomers include hydrogen bonds and hydrophobic interactions as shown in 
Fig. 4.31 and 4.32 for the inactive conformation.  
The inactive conformation of ∆N-HtrA1 shows a misarranged activation domain as well as a flexible 
loop L3 and therefore typical features of an inactive HtrA protease as described for DegP (Krojer et 
al. 2002) and DegS (Wilken et al. 2004). Another typical feature for inactive serine proteases is a not 
properly formed oxyanion hole. This characteristic is described for human HtrA2, HtrA from T. 
maritima and inactive DegS. Here the NH donor of residue 193 (using the trypsin nomenclature) is 
flipped to the opposite side of the protein backbone. Therefore an oxyanion intermediate can not be 
stabilized (Fig. 5.1 A).  
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Fig. 5.1 Inactive conformation of HtrA1 
A) Alignment of human HtrA2 (blue, residues 170-174, PDB entry code 1LCY), HtrA from T. maritima (grey, residues 203-207, PDB entry 
code 1L1J), inactive DegS from E. coli (magenta, residues 198-202, PDB entry code 1SOT) and human HtrA1 (yellow, residues 325-329) B) 
Alignment of inactive and active conformation of human HtrA1 (yellow and green respectively). The structures of the protease domain of 
HtrA1 (light blue) and for the inactive mutant of ∆N-HtrA1 (grey) are superimposed. Mechanistically important loops are indicated: loop L1 
in green, loop L2 in red, loop L3 in orange and loop LD in magenta. The side chains for catalytic triad are shown in stick and ball mode. Note 
that loop L3 is disordered in both structures.  
 
 
A superimposition of the structures of the HtrA-prot and ∆N-HtrA1 shows that both proteins are 
present in an inactive conformation (Fid. 5.1 B). They align with an rmsd of 0.6 Å showing no 
significant differences neither for the loops setting up the catalytic site nor for the remaining part of 
the protease domain. As the protein without the PDZ domain is active it would have been also 
possible to observe the active conformation. Loop L3 is not defined in both inactive conformations of 
∆N-HtrA1 and HtrA1-prot therefore a possible interaction with the PDZ domain and any influence on 
the conformation of the protease domain can not be discussed.  
5.3 Active conformation of HtrA1 
To solve the crystal structure of an enzyme-inhibitor complex is a general tool to assess the 
mechanism of a certain enzyme. Here ∆N-HtrA1 was co-crystallized with a boronic acid based 
inhibitor. Peptide boronic acids are described as potent proteasome (Adams et al. 1998) and serine 
protease inhibitors (Bode and Huber, 2000). The inhibition can take place in two different modes. 
Boronic acids which are analogues of substrates bind in a canonical manner with the boron atom 
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covalently attached to the active site serine. In contrast boronic acids which are not substrates 
analogous can form complexes with the active site histidine (Bachovchin et al. 1988).  
The first mode is characterized by several inter-main chain hydrogen bonds of the inhibitor with 
proteinase binding sites. The scissile peptide bond is partially added to the active site serine. The P1 
side chain is pointing into the S1 specificity pocket. Altogether the peptide inhibitor undergoes 
numerous substrate-like interactions (Bode and Huber, 2000).  
The peptide boronic acid DPMFKLboroV interacts with HtrA1 in a canonical mode. Three hydrogen 
bonds between P1, P2, P3 and the backbone of HtrA1 in beta sheet 11 stabilize the binding of the 
inhibitor (Fig. 5.2 A). The boron atom is covalently bound to the active site serine forming a 
tetrahedral state with the O stabilized by hydrogen bonds in the oxyanion hole and the P1 residue 
pointing into the S1 specificity pocket (Fig. 5.2 B). 
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Fig. 5.2 Binding of the peptide boronic acid inhibitor in a substrate like manner 
A) Residues are shown in stick and ball presentation. Loop L1 (green), L2 (red), and L3 (orange) are indicated. The peptide inhibitor is 
hydrogen bonded to residues in beta sheet 8 binding in a canonical fashion. B) The peptide inhibitor is covalently attached to the active site 
serine. B) The O¯ of the boronic acid is stabilized by hydrogen bonds in the oxyanion hole. Residues are despicted in stick and ball mode, 
HtrA1 protease residues in green (325-329 in loop L1 and Ile323 and Lys346 building the S1 specificity pocket), inhibitor residues in yellow 
(LboroV). The DegP active conformation of loop L1 (residues 207-211, PDB entry 3CS0) is superimposed in orange.  
 
Interestingly, the bacterial homologs of HtrA1 exhibit exactly the same active site geometry in their 
respective active states. In the activated form of DegS and DegP the backbone atoms are rearranged 
and loop L1 adopts a conformation similar to trypsin. This can be also observed for HtrA1 (Fig. 5.2 B). 
A structure based sequence alignment with homologues of HtrA1 indicates that residues Ile323 and 
Lys346 are equivalents of the positions 192 and 216 in trypsin-like serine proteases and Ile205 and 
Ile228 in DegP. These amino acids usually extend into the S1 pocket, where they partially or fully 
block access to the base of the pocket. For HtrA1 it can be proposed that the conserved isoleucine 
and the aliphatic side chain of lysine play a similar role in the active protease, providing the basis for 
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the interaction with small, hydrophobic P1
 
residues of substrates. Consistent with this notion, 
complete digests of CS and MDH indicated a corresponding preference (Fig. 4.21). Consistently, DegP 
has a preference for an aliphatic β-branched residue such as valine at the P1
 
position but no obvious 
preference for the P1’ position (thesis Tobias Krojer, 2004) which is also true for HtrA1 (Fig. 4.22). 
More interestingly the peptide inhibitor was able to trigger the active conformation of HtrA1. This 
was also possible even though HtrA1 shows no proteolytic activity at pH 5.4 to 6.3 where co-
crystallization trials were set up. Superimposements of the active conformation of HtrA1 with the 
active conformations of DegS and DegP shows that loops L1 and LD aligned perfectly to each other 
and loop L2 and L3 aligned in the stem region (Hasselblatt et al. 2007, data not shown) which is 
confirming the active conformation of HtrA1. Nevertheless the HtrA structures also display significant 
differences in their active site architecture. Sequence alignments of human HtrA1 and HtrA2 and E. 
coli DegP and DegS, illustrate that the human proteins exhibit specific truncations in several loop 
regions with respect to DegP including for example loop L3 which shows an insertion of 5 amino acids 
for HtrA1 in comparison to DegP. In contrast loop L2, which determines the substrate specificity, 
consists of only 2 residues in HtrA1 and shows an insertion of three amino acids for DegS compared 
to DegP. Loop LA is completely absent in human HtrA1 and HtrA2.  
For DegP the release of loop LA from the active site of the opposite monomer is crucial to obtain the 
active conformation. During oligomerization conformational changes take place which lead to the 
release of loop LA. Subsequently loop L1 can fold into the turn structure needed to build up a proper 
oxyanion hole (Krojer et al. 2008).  
For DegS Loop L3 is communicating with the PDZ domain sensing a bound stress peptide and 
interacting with the -1 position in the peptide. Thereby loop L3 undergoes conformational changes 
which lead in turn to the rearrangement of loops L1, L2 and LD and an active site conformation.  
In the HtrA1 structure co-crystallization with the peptide inhibitor leads to a disorders orderd 
transition of loop L3. This is due to hydrophobic interactions with the inhibitor peptide at position P4 
and P2 and leads to the rearrangement of loop L1 and a proper set-up of the oxyanion hole (Fig. 5.3 
A) as well as loop L2 and LD. The catalytic triad residues are hydrogen bonded (Fig. 5.3 B). 
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Fig. 5.3 Conversion from the inactive to the active conformation 
A) Residues of the catalytic triad are shown in stick and ball presentation. Green residues confirm the active residues for the active 
conformation, yellow residues for the inactive conformation. In the active conformation Asp250 is in hydrogen bond distance to His220 
and His220 to Ser328. In the inactive conformation Ser328 is replaced by Ala328. B) Formation of the oxyanion hole. Loop L1, residues 325-
329 of inactive and active conformation. 
 
In the active conformation loop L2 undergoes interactions with L1 in the adjacent monomer. The side 
chain of Thr348 in loop L2 interacts with the side chain of Asn324* (L1*) in the adjacent monomer. L1 
forms also intramonomeric interactions with loop LD as Tyr325 (L1) interacts with Phe286 in loop LD. 
In comparison in the inactive conformation Tyr325 in loop L1 interacts with Thr348* in loop L2*. 
Loop L2 is ‘longer‘ in the inactive conformation as some residues of it are part of ß sheet 11 in the 
active conformation.  
It is quite remarkable that there was no electron density for the PDZ domains of HtrA1 in the active 
state. Thus conversion from the inactive into the active state is triggered without contribution of the 
PDZ domains. This is in contrast to all data published for structures of human or bacterial family 
members including tmHtrA, HtrA2, DegP and DegS (MohamedMohaideen et al. 2008, Krojer et al. 
2008, Kim et al. 2003) where the protease-PDZ interplay is critical for enzymatic regulation. For 
example, in DegS, the PDZ domain regulates the proteolytic activity by offering a binding site for an 
allosteric peptide activator that signals protein folding stress. Moreover, in the non-stress situation, 
i.e. in the absence of an activator, the PDZ domain is required to keep the protease in the resting 
state (Wilken et al. 2004, Hasselblatt et al. 2007, Walsh et al. 2003). In contrast, DegP employs its 
PDZ domain 1 for processive substrate degradation by an interdomain protease-PDZ molecular ruler 
(Meltzer et al. 2008, Krojer et al. 2008). Furthermore, the PDZ domain 1 of DegP is directly involved 
in the conversion of the resting hexamer into the functional 12- and 24-mers by stabilizing the 
DegP12/24 interfaces. Finally for human HtrA2 it was proposed that the PDZ domains restrict entry 
to the active site thereby exerting an inhibitory effect on the catalytic activity (Li et al. 2002). 
Consequently HtrA2 shows increased activity in ß-casein digests when PDZ domain deletion 
Discussion         106 
 
constructs are incubated with the substrate. HtrA2 exhibit full enzymatic activity only when 
activating peptides bind to the PDZ domain (Li et al. 2002). 
For HtrA1 slightly increased activity could also be examined for ß-casein degradation but not for 
degradation of substrates like unfolded CS, MDH or Lysozyme.  
Because the PDZ domains were not defined by electron density it can be concluded that they do not 
block the active site as observed in human HtrA2. Most likely they protrude outwards as suggested 
by the crystal packing. 
Inhibition by the peptide inhibitor is achieved when added in more than 10 fold molar excess to 
HtrA1. The inhibitor binds with a Ki of 2.6 μM as determined in pNA cleavage assays (personal 
communication). Optimized boronic acid inhibitors containing analogous for good peptide substrates 
are bound in a range of 0.1 to 20 nM (Kettner et al. 1984). Thus the binding and inhibition of the 
inhibitor could be optimized. Two conclusions can be drawn from the binding mode of the peptide 
inhibitor for the design of improved versions of the inhibitor. First interactions between inhibitor and 
protease domain are mainly mediated by the side chains of threonine at P2 and phenylalanine at P4 
position. A network of hydrophobic interactions formed with loop L3 and these two residues seems 
to be important and help to order loop L3. Second the phenylalanine at P4 position seems to be 
“squeezed” between the inhibitor backbone and beta sheet 8 of the protease domain as it is slightly 
bended (Fig. 4.34). The substitution with a smaller hydrophobic residue like valine or isoleucine could 
improve the binding features. Conclusively when analysing the complete digests of CS and MDH for 
the P4 position mainly small residues as leucine followed by serine, threonine, alanine, glycine and 
valine were found.  
5.4 Role of the PDZ domains 
Much effort was spent into the determination of the structure and position of the PDZ domains in 
order to clarify their role for HtrA1. As discussed above the absence of intramolecular interactions 
between protease and PDZ domain is in contrast to all known structures of human or bacterial family 
members. 
Biochemical assays with ß-casein showed that for HtrA1 the PDZ domains are not required for 
proteolytic activity. For the bacterial homolog DegP the PDZ domains are indispensable for 
proteolysis (Krojer et al. 2008). Deletion constructs of DegS and human HtrA2 which lack their 
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respective PDZ domain show moderate proteolytic activity if lacking the PDZ domain (Li et al. 2002) 
and are only fully enzymatic active if activated with peptides binding to the PDZ domains. In assays 
with the synthetic substrate VFNTLPMMGKASPV-pNA the rate of the substrate degradation is slightly 
decreased by deleting the PDZ domain suggesting that the PDZ domain does not significantly 
contribute to the activity of HtrA1. In pNA assays with VFNTLPMMGKASPV-pNA as substrate and 5 
μM of the peptide KKKDSRIWWV which was shown to bind to the PDZ domain of HtrA1, protease 
activity could be activated but with 30% activation was only marginal increased. Increased activity 
was not observed for HtrA1-prot. ITC measurements indicate that the PDZ domain is required for the 
binding of peptides. Taken together this would lead to the conclusion that the PDZ domain like in 
related structures is important for binding peptides and for modulating protease activity. Further 
experiments with different and optimized peptides have to be done.  
In complete digests of denatured MDH or CS it became obvious that the PDZ domain has in addition 
an influence on the length of the peptide products. Peptides derived with HtrA1 lacking the PDZ 
domain appeared to be 5 AA shorter. In DegP PDZ and protease domain cooperate to cleave 
substrates in a processive manner (Krojer et al. 2008).  Substrates are held by the PDZ domain and 
cut by the protease domain. One possible explanation for shortened peptides in HtrA1-prot cleavage 
assays could be that one catalytic side is holding the substrate instead of the PDZ domain. In 
agreement the catalytic sites in a HtrA1 trimer are separated by approx. 30 Å and could thus be 
bridged by a 10 amino acid peptide (Fig. 5.4).  
29.8 Å
 
Fig. 5.4 Distance of the active sites in HtrA1 trimer 
The trimer of the protease domain is shown as cartoon, coloured differently for each monomer. The catalytic sites are shown in stick and 
ball presentation. The triangle indicates the distance from one active site serine to the active site serine in the adjacent monomer which is 
calculated with 29.8 Å. 
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HtrA1 was found to build a homotrimer in inactive and active conformation. Interactions with the 
PDZ domains could not be determined due to the high flexibility of the domains. According to the 
model of DegP it could be speculated that the PDZ domains maintain interactions to form a 12mer of 
HtrA1. That would explain why they were found to be highly flexible in a trimer. In contrast HtrA1 
incubated with the peptide found via ITC to bind to the PDZ domain of HtrA1 does not trigger 
oligomerization as concluded from SEC (data not shown). Furthermore PDZless protein forms higher 
oligomers. Therefore co-crystallization with an unfolded substrate like CS or lysoyzme would be an 
aim for the future to get insight into action of the PDZ domain. On the other hand given the results 
that the PDZ domain is dispensable for oligomerization and enzymatic activity one could speculate 
that the PDZ domains are required for tethering HtrA1 to the places within the cell where HtrA1 is 
required. Chien et al. showed recently that HtrA1 is located to microtubules and that the PDZ domain 
is indispensable for location (Chien et al. 2009). 
In ß-casein cleavage assays ∆N-HtrA1 was decelerated in cleaving ß-casein degradation products 
compared to PDZless HtrA1 which higly efficiently cleaved the degradation products. As a certain 
cleavage product remained over minutes (Fig. 4.15) one could speculate that the PDZ domain is 
holding cleavage products which are not immedeatly further processed by the PDZ domain as 
indicated in the figure below. To date it is completely unknow if this model is true and for whatever 
function this feature would be necessary. 
 
Prot PDZ Prot PDZ Prot PDZ  
Fig. 5.5 Role of the PDZ domain 
Unfolded substrates (green) are bound by protease and PDZ domain. After cleavage the peptide product remains bound to the PDZ 
domain.  
5.5 Quaternary structure of HtrA1 in solution  
Through size-exclusion chromatography and dynamic light scattering measurements, it could be 
verified that ∆N-HtrA1
 
is predominantly present as a trimer in solution. Interestingly, higher 
molecular species could be detected in the presence of unfolded substrates. It was shown that these 
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species emerge in the presence of denatured and unfolded lysozyme, CS, bacterial OmpA and ß-
casein. So far no studies are available describing a high oligomeric state for HtrA1 or a human 
homolog in solution. For the bacterial homolog DegP it has been confirmed that it exists either as a 
hexamer in solution (Sassoon et al. 1999), but that it forms 12 and 24meric particle (Kim et al. 1999, 
Krojer et al. 2008). For DegP this conversion into a higher oligomeric state is accompagnied with a 
structural conversion of an inactive into an active proteolytic site as DegP converts from the inactive 
resting state (hexamer) into the active form as 12- or 24mer. Thus it is tempting to speculate that the 
detected oligomer for HtrA1 represents a conserved form of activation. Comparison of the elution 
volumes for DegP 12mer and HtrA1 show that DegP elutes slightly earlier from the column (1.08 ml 
DegP12mer, 1.22 HtrA1 oligomer with CS) corresponding to a difference of approx. 70 kDa. This is in 
agreement with the fact that DegP contains two instead of one PDZ domains (approx. 10 kDa) 
compared to HtrA1. Thus the species could represent a 12mer of HtrA1. Additionally this finding is 
supported by preliminary EM data showing particles with a diameter of 120 Å, which is comparable 
to the diameter of 160 Å for a DegP 12mer (Krojer et al. 2008). Furthermore in pNA assays activity 
increase in the presence of unfolded CS. To draw conclusions about the stoichiometry of HtrA1 and 
the substrate is rather difficult. DLS measurements reveal a particle with 670 kDa which would 
correspond to a 12mer of HtrA1 and 4 molecules of unfolded CS. 
For DegS and HtrA2 no chaperone activity has been reported but for DegP and HtrA from T. maritima 
experiments demonstrated that this protein also possesses both functionalities (Kim et al. 2003, 
Spiess et al. 1999). For HtrA1 it became obvious that during incubation with lysoyzme and CS HtrA1 is 
able to keep both proteins in solution and to prevent aggregation a fact that points towards an 
activity of HtrA1 to suppress aggregation of unfolded substrates, most likely by encapsulating 
unfolded proteins. 
DegP is capable to form 12 and 24meric particles depending on the concentration and the size of the 
substrate (Krojer et al. 2008). However both PDZ domains are involved in 24mer formation whereas 
the crucial contacts in the 12mer are entirely formed via the PDZ1 domain (Krojer et al. 2008). For 
HtrA1 only one oligomeric species could be observed in the presence of unfolded protein, which 
corresponds to the fact that it contains only one PDZ domain and thus may only be able to form 
12meric complexes.  
For DegP the PDZ domains are indispensable for oligomerization (Sassoon et al. 1999). In contrast for 
HtrA1 it was shown in this thesis that the PDZ domain is dispensable for oligomer conversion i.g. also 
without the PDZ domain higher oligomeric species could be determined. These species elute later 
from the column (1.18 ml) corresponding to a molecular mass difference of approx. 75 kDa. It turned 
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out that this complex is less stable compared to the one with the PDZ domains. When a previously 
isolated complex was reinjected to the column a significant amount of trimeric HtrA1-prot and CS 
occurred. In pNA assays the activity of HtrA1-prot was increased if incubated with unfolded CS. This 
suggests a new mechanism of activation due to the fact that the PDZ domains can not be part of the 
new interface in a higher oligomer of HtrA1-prot. 
At this point further experiments will be necessary to clarify if the 12mer is one existing form for 
HtrA1 and for HtrA1-prot. Cryo EM studies could be one possibility. Obviously it would be absolutely 
interesting to solve the crystal structure of a HtrA1 12mer to get insight into the mode of action of 
HtrA1.  
5.6 Possible activation mechanisms 
Finally the question arises how HtrA1 activity is regulated. What could be the activation mechanism 
and how could HtrA1 be controlled? If it would be possible to control the proteolytic activity of HtrA1 
it could be a good candidate for therapeutical interventions as HtrA1 was shown to be upregulated 
during arthrits (Grau et al. 2005) and ageing (Ly et al. 2000) and downregulated during Alzheimers`s 
disease (Grau et al. 2005). For several members of the HtrA family activation mechanisms have been 
described. DegP is controlled by temperature DegS by binding of substrates to the PDZ domain, 
HtrA2 by the binding of trimeric ligands (Li et al. 2002). Recently it was proposed that HtrA from 
Mycobacterium tuberculosis is regulated by auto proteolysis (Mohamedmohaideen et al. 2008) as in 
both the active site and the binding site of the PDZ domain auto proteolytic peptides were found. 
During purification of full length HtrA1 strong auto degradation was observed for the wt protein 
resulting in a fragment comprising the C-terminal protease and PDZ domain. The N-terminus of 
HtrA1 contains a predicted Kazal-like inhibitor domain. Kazal inhibitory domains are known to inhibit 
proteases of the trypsin family (Bode et al. 1992, Van de Locht et al. 1995).  
At the moment it is not clear if auto proteolysis corresponds to an additional mechanism for 
regulating the protease activity of HtrA1. Mapping the cleavage sites by N-terminal sequencing and 
subsequent mutation would reveal if HtrA1 is still active under these conditions and if forming of 
higher oligomers upon substrate binding is still possible or if the N-terminus has to be cleaved. 
Additionally co-crystallization of C- and N-terminus of HtrA1 could show possible binding of the 
Kazal-like inhibitory domain to HtrA1 itsself.  
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When testing the ability of HtrA1 to form higher oligomers it was observed that oligomerization is pH 
dependent. HtrA1 was incubated with unfolded CS in pH 7.5, 8, 8.5 and 9. Clearly conversion into the 
oligomer increased with increasing pH (Fig. 5.5). Conclusively no activation was observed in pNA 
assays at pH 7.5. 
During biochemical characterization of HtrA1 it became also obvious that only completely unfolded 
proteins were cleaved which could be another mechanism to prevent unwanted proteolysis. 
Lysoyzme was only degraded and captured when fully denatured that means denaturation with urea 
was not sufficient and addition of at least 20 mM DTT was required. The same result was observed 
for CS and MDH which had to be denatured at 42°C prior to degradation. Consistently no higher 
oligomers occurred when incubating HtrA1 and CS at 37°C. It can be speculated that folded 
substrates are too bulky to enter the active site or the S1 specificity pocket. In the trimeric structure 
of HtrA1 the active site is freely accessible to solvent thus one could speculate that the PDZ domains 
influence the access or that in a 12mer of HtrA1 only unfolded proteins can be captured. 
Another activation mechanism is shown in figure 5.6. Given the fact that the peptide inhibitor is 
capable to trigger the active conformation, substrates or peptides binding to the active site could 
lead to activation in cis, i.e. within the trimer, without contribution of the PDZ domain (Fig. 5.6). 
 
S S S
S
Cis activationS
 
Fig. 5.6 Model for HtrA1 activation in cis 
Substrates (S) bind to the one active site in a HtrA1 trimer and trigger the active conformation. This leads in turn to the activation of the 
other two  monomers within the trimer (in cis activation). 
 
Activation in trans, i.e. between different trimers of HtrA1 could be present if unfolded substrate is 
bound. As so far it can not be stated how HtrA1 binds to unfolded substrates two different modes 
could be considered (Fig. 5.7). Either HtrA1 is able to form defined particles like DegP or it may 
cluster around unfolded substrates to prevent aggregation and subsequently cleave them. 
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Fig. 5.7 Model for activation of HtrA1 in trans 
HtrA1 binds unfolded substrates either by binding along the substrate or by forming defined particles around the substrate. Activation may 
occur between different trimers (in trans activation). 
 
 
To decide between both models depicted in Fig. 5.7 one could identify by mass spectrometry the 
ration of HtrA1 to unfolded substrate which would be a clear indicator. 
Taken together the results imply that HtrA1 could play a role as a rather unspecific housekeeping 
protease degrading unfolded proteins which may probably aggregate. HtrA1 could be thus 
considered playing a role in the protein quality control in the ECM like DegP in the periplam of E. coli. 
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6 Conclusions 
Three crystal structures were presented for human HtrA1. They show the protease domain in the 
inactive and active conformation. Both states share common structural features with other members 
of the HtrA family. But they also show striking mechanistic differences.  
Interestingly, binding of the peptide inhibitor to the active site of the protease domain alone leads to 
conformational changes of all active site loops setting up the active conformation. Most prominently 
loop L3 becomes ordered showing defined interactions with the peptide inhibitor. This observation is 
different to known HtrA structures where loop L3 becomes ordered by specific interactions with the 
PDZ domain or to a stress peptide bound to the PDZ domain in DegS.  
In bacterial HtrAs the PDZ domains function as sensors of protein folding stress, binding sites for 
substrates, regulators of the enzymatic activity and are required for oligomerization. In human HtrA1 
they are dispensable for proteolytic activity but are involved in allosteric regulation. Furthermore 
they influence the product size of cleaved substrates.  
Most interestingly these data also suggest that human HtrA1 could be regulated by a conserved 
mechanism of activation by oligomerization which was first described for bacterial DegP (Krojer et al. 
2008). It could not be shown for DegS or human HtrA2. It is therefore exciting to speculate that in 
analog to DegP HtrA1 establishes a packaging device that is able to sequester unfolded proteins for 
partitioning between refolding and degradation pathways. Thus it could be considered as a part of 
the protein quality control in the ECM which is not yet characterized.  
Although the crystal structures of HtrA1 and biochemical analysis have enlarged our knowledge 
about HtrA1, there is still a great number of open questions regarding the regulation of this family 
member. Therefore the presented results could be the guide for future experiments that will allow a 
detailed view into the activation mechanism of human HtrA1. 
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7 Zusammenfassung 
HtrA1 gehört zur Familie der HtrA (High temperature requirement) Serin-Proteasen, einer Gruppe 
hochkonservierter Proteasen, die sowohl eukaryotische als auch prokaryotische Mitglieder umfasst. 
Gemeinsames Merkmal dieser Serin-Proteasen ist das Vorhandensein einer hoch-konservierten 
Trypsin-ähnlichen Domäne und mindestens einer C-Terminalen PDZ-Domäne. HtrA1 wurde 
ursprünglich als weniger exprimiertes Gen in SV40-transfomierten Fibroblasten identifiziert und wird 
außerdem mit verschiedenen Krankheitsbildern, wie Arthritis, altersbedingter Makuladegeneration 
oder der Alzheimerschen Krankheit in Verbindung gebracht.  
In dieser Arbeit werden drei Kristallstrukturen von HtrA1 präsentiert. Sie zeigen die Protease 
Domäne in der inaktiven und aktiven Konformation. Beide Konformation weisen vergleichbare 
strukturelle Gegebenheiten im Vergleich mit anderen HtrA Familienmitgliedern auf. Zugleich werden 
aber signifikante Besonderheiten für HtrA1 deutlich.  
Interessanterweise ist die Bindung des Peptid-Inhibitors in das aktive Zentrum der Protease Domäne 
ausreichend, um konformationelle Änderungen hervorzurufen, die durch Reorientierung der 
Schleifen, die das aktive Zentrum gestalten, von einer inaktiven zu einer aktiven Konformation 
führen. Schleife L3, die in der inaktiven Konformation ungeordnet ist, zeigt jetzt eine geordnete 
Konformation und definierte Interaktionen mit dem Inhibitor molekül. Diese Erkenntnis ist 
unterschiedlich zu vergleichbaren bekannten HtrA Strukturen in denen L3 eine geordnete 
Konformation durch spezifische Interaktionen mit der PDZ Domäne einnimmt.  
Die PDZ Domänen der bakteriellen HtrAs sind wichtig für die Erfassung von Protein Faltungsstress, sie 
sind Bindungsstellen für Substrate und regulieren die enzymatische Aktivität. Für das humane HtrA1 
konnte gezeigt werden, dass die PDZ Domäne entbehrlich für die katalytische Aktivität ist, aber eine 
Rolle für die allosterische Regulation von HtrA1 spielt. Außerdem beeinflusst die PDZ Domäne die 
Produktlänge von geschnittenen Substraten.  
Vor allem interessant ist, daß die Daten auch auf die Möglichkeit hindeuten, daß die Protease durch 
einen konservierten Mechanismus der Oligomerisierung reguliert wird. Dieser Mechanismus der 
Regulation durch Oligomerisierung wurde zuerst für das bakterielle Familienmitglied DegP 
beschrieben (Krojer et al. 2008), konnte aber nicht für bakterielles DegS oder humanes HtrA2 gezeigt 
werden. Es ist daher spannend zu spekulieren, dass HtrA1 analog zu DegP ein Molekül darstellt, das 
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in der Lage ist ungefaltete oder fehlgefaltete Proteine zu sequestrieren, um es der Rückfaltung oder 
dem Abbau zuzuführen. Damit könnte es ein Teil der Stressantwort auf ungefaltete Proteine in der 
ECM sein, ein Qualitäts-Kontrollsystem das noch nicht sehr characterisiert ist.  
Obwohl die hier präsentierten Kristallstrukturen von HtrA1 und die biochemischen Analysen unser 
Wissen über HtrA1 erweitern, ist die Zahl der offenen Fragen immer noch immens. Die dargestellten 
Ergebnisse können somit die Grundlage für wichtige Experimente in der Zukunft bilden, die einen 
weiterführenden Einblick in den Mechanismus der Aktivierung der humanen Serin-Protease HtrA1 
ermöglichen. 
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